WO2024047247A1 - Approches d'édition de bases pour le traitement de la sclérose latérale amyotrophique - Google Patents
Approches d'édition de bases pour le traitement de la sclérose latérale amyotrophique Download PDFInfo
- Publication number
- WO2024047247A1 WO2024047247A1 PCT/EP2023/074086 EP2023074086W WO2024047247A1 WO 2024047247 A1 WO2024047247 A1 WO 2024047247A1 EP 2023074086 W EP2023074086 W EP 2023074086W WO 2024047247 A1 WO2024047247 A1 WO 2024047247A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- c9orf72
- sequence
- base
- editing
- rna
- Prior art date
Links
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 title claims abstract description 31
- 238000011282 treatment Methods 0.000 title abstract description 18
- 238000013459 approach Methods 0.000 title abstract description 13
- 101150014718 C9orf72 gene Proteins 0.000 claims abstract description 59
- 108700030955 C9orf72 Proteins 0.000 claims abstract description 53
- 102000043334 C9orf72 Human genes 0.000 claims abstract description 49
- 230000014509 gene expression Effects 0.000 claims abstract description 38
- 108020005004 Guide RNA Proteins 0.000 claims abstract description 34
- 102000009572 RNA Polymerase II Human genes 0.000 claims abstract description 25
- 108010009460 RNA Polymerase II Proteins 0.000 claims abstract description 25
- 238000010362 genome editing Methods 0.000 claims abstract description 21
- 239000013598 vector Substances 0.000 claims description 59
- 108091033409 CRISPR Proteins 0.000 claims description 53
- 101710163270 Nuclease Proteins 0.000 claims description 53
- 238000000034 method Methods 0.000 claims description 40
- 102000004190 Enzymes Human genes 0.000 claims description 33
- 108090000790 Enzymes Proteins 0.000 claims description 33
- 238000010453 CRISPR/Cas method Methods 0.000 claims description 31
- 108020004414 DNA Proteins 0.000 claims description 28
- 125000003729 nucleotide group Chemical group 0.000 claims description 21
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 20
- 230000035772 mutation Effects 0.000 claims description 19
- 239000002773 nucleotide Substances 0.000 claims description 18
- 238000006243 chemical reaction Methods 0.000 claims description 15
- 230000002950 deficient Effects 0.000 claims description 14
- 108010031325 Cytidine deaminase Proteins 0.000 claims description 12
- 108010008532 Deoxyribonuclease I Proteins 0.000 claims description 11
- 102000007260 Deoxyribonuclease I Human genes 0.000 claims description 11
- 241000193996 Streptococcus pyogenes Species 0.000 claims description 10
- 239000013603 viral vector Substances 0.000 claims description 7
- 230000001965 increasing effect Effects 0.000 claims description 6
- 102220605874 Cytosolic arginine sensor for mTORC1 subunit 2_D10A_mutation Human genes 0.000 claims description 5
- 102100026846 Cytidine deaminase Human genes 0.000 claims 2
- 238000005516 engineering process Methods 0.000 abstract description 14
- 230000008685 targeting Effects 0.000 abstract description 13
- 238000013518 transcription Methods 0.000 abstract description 13
- 230000035897 transcription Effects 0.000 abstract description 12
- 238000013461 design Methods 0.000 abstract description 7
- 230000001225 therapeutic effect Effects 0.000 abstract description 6
- 108700039691 Genetic Promoter Regions Proteins 0.000 abstract description 4
- 231100000419 toxicity Toxicity 0.000 abstract description 4
- 230000001988 toxicity Effects 0.000 abstract description 4
- 230000009437 off-target effect Effects 0.000 abstract description 2
- 230000003827 upregulation Effects 0.000 abstract description 2
- 210000004027 cell Anatomy 0.000 description 79
- 108090000623 proteins and genes Proteins 0.000 description 52
- 150000007523 nucleic acids Chemical class 0.000 description 46
- 239000013612 plasmid Substances 0.000 description 38
- 230000001177 retroviral effect Effects 0.000 description 38
- 102000039446 nucleic acids Human genes 0.000 description 36
- 108020004707 nucleic acids Proteins 0.000 description 36
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 35
- 102000004169 proteins and genes Human genes 0.000 description 29
- 235000018102 proteins Nutrition 0.000 description 28
- 108020004999 messenger RNA Proteins 0.000 description 23
- 235000001014 amino acid Nutrition 0.000 description 22
- 208000031752 chronic bilirubin encephalopathy Diseases 0.000 description 21
- 150000001413 amino acids Chemical class 0.000 description 20
- 230000000295 complement effect Effects 0.000 description 20
- 239000002245 particle Substances 0.000 description 20
- 108090000765 processed proteins & peptides Proteins 0.000 description 19
- 125000005647 linker group Chemical group 0.000 description 18
- 108091079001 CRISPR RNA Proteins 0.000 description 17
- 108091027544 Subgenomic mRNA Proteins 0.000 description 17
- 102000004196 processed proteins & peptides Human genes 0.000 description 16
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 15
- 239000002609 medium Substances 0.000 description 15
- 241000700605 Viruses Species 0.000 description 14
- 230000000694 effects Effects 0.000 description 14
- 239000002502 liposome Substances 0.000 description 14
- 210000002161 motor neuron Anatomy 0.000 description 14
- 241000282414 Homo sapiens Species 0.000 description 13
- 229920001184 polypeptide Polymers 0.000 description 13
- 108091028043 Nucleic acid sequence Proteins 0.000 description 12
- 238000004458 analytical method Methods 0.000 description 12
- 230000006870 function Effects 0.000 description 12
- 239000003814 drug Substances 0.000 description 11
- 238000007480 sanger sequencing Methods 0.000 description 11
- 238000001890 transfection Methods 0.000 description 11
- 102000005381 Cytidine Deaminase Human genes 0.000 description 10
- 101710143275 Single-stranded DNA cytosine deaminase Proteins 0.000 description 10
- 102100022433 Single-stranded DNA cytosine deaminase Human genes 0.000 description 10
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 description 10
- 230000004570 RNA-binding Effects 0.000 description 9
- 235000019877 cocoa butter equivalent Nutrition 0.000 description 9
- 238000000338 in vitro Methods 0.000 description 9
- 230000001404 mediated effect Effects 0.000 description 9
- 230000027455 binding Effects 0.000 description 8
- 201000010099 disease Diseases 0.000 description 8
- 229940079593 drug Drugs 0.000 description 8
- 108020001507 fusion proteins Proteins 0.000 description 8
- 102000037865 fusion proteins Human genes 0.000 description 8
- 230000002068 genetic effect Effects 0.000 description 8
- 239000000203 mixture Substances 0.000 description 8
- 229930024421 Adenine Natural products 0.000 description 7
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 7
- 108091026890 Coding region Proteins 0.000 description 7
- 201000011240 Frontotemporal dementia Diseases 0.000 description 7
- 101710125418 Major capsid protein Proteins 0.000 description 7
- 229960000643 adenine Drugs 0.000 description 7
- 208000035475 disorder Diseases 0.000 description 7
- 238000012423 maintenance Methods 0.000 description 7
- 238000011529 RT qPCR Methods 0.000 description 6
- 230000000981 bystander Effects 0.000 description 6
- 229940104302 cytosine Drugs 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- 238000009396 hybridization Methods 0.000 description 6
- 230000004048 modification Effects 0.000 description 6
- 238000012986 modification Methods 0.000 description 6
- 230000001105 regulatory effect Effects 0.000 description 6
- 238000006467 substitution reaction Methods 0.000 description 6
- 238000011285 therapeutic regimen Methods 0.000 description 6
- 241001515965 unidentified phage Species 0.000 description 6
- 101710132601 Capsid protein Proteins 0.000 description 5
- 101710094648 Coat protein Proteins 0.000 description 5
- 102000053602 DNA Human genes 0.000 description 5
- 238000007400 DNA extraction Methods 0.000 description 5
- 102100021181 Golgi phosphoprotein 3 Human genes 0.000 description 5
- 108010043121 Green Fluorescent Proteins Proteins 0.000 description 5
- 102000004144 Green Fluorescent Proteins Human genes 0.000 description 5
- 241000713772 Human immunodeficiency virus 1 Species 0.000 description 5
- 101710141454 Nucleoprotein Proteins 0.000 description 5
- 101710083689 Probable capsid protein Proteins 0.000 description 5
- 125000000539 amino acid group Chemical group 0.000 description 5
- 238000004422 calculation algorithm Methods 0.000 description 5
- 150000001875 compounds Chemical class 0.000 description 5
- 238000012217 deletion Methods 0.000 description 5
- 230000037430 deletion Effects 0.000 description 5
- 230000005782 double-strand break Effects 0.000 description 5
- 239000005090 green fluorescent protein Substances 0.000 description 5
- 239000001257 hydrogen Substances 0.000 description 5
- 229910052739 hydrogen Inorganic materials 0.000 description 5
- 230000006698 induction Effects 0.000 description 5
- 150000002632 lipids Chemical class 0.000 description 5
- 230000004770 neurodegeneration Effects 0.000 description 5
- 238000004806 packaging method and process Methods 0.000 description 5
- 102000040430 polynucleotide Human genes 0.000 description 5
- 108091033319 polynucleotide Proteins 0.000 description 5
- 239000002157 polynucleotide Substances 0.000 description 5
- 238000000746 purification Methods 0.000 description 5
- 230000010076 replication Effects 0.000 description 5
- 125000006850 spacer group Chemical group 0.000 description 5
- 230000003612 virological effect Effects 0.000 description 5
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 4
- -1 DNA) Chemical class 0.000 description 4
- ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical compound O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 description 4
- DRTQHJPVMGBUCF-XVFCMESISA-N Uridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-XVFCMESISA-N 0.000 description 4
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 description 4
- 230000004900 autophagic degradation Effects 0.000 description 4
- 238000006481 deamination reaction Methods 0.000 description 4
- 230000004927 fusion Effects 0.000 description 4
- 238000003780 insertion Methods 0.000 description 4
- 230000037431 insertion Effects 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 238000002703 mutagenesis Methods 0.000 description 4
- 231100000350 mutagenesis Toxicity 0.000 description 4
- 229920000642 polymer Polymers 0.000 description 4
- 238000012545 processing Methods 0.000 description 4
- 229930002330 retinoic acid Natural products 0.000 description 4
- 230000002441 reversible effect Effects 0.000 description 4
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 4
- 229960001727 tretinoin Drugs 0.000 description 4
- UHDGCWIWMRVCDJ-UHFFFAOYSA-N 1-beta-D-Xylofuranosyl-NH-Cytosine Natural products O=C1N=C(N)C=CN1C1C(O)C(O)C(CO)O1 UHDGCWIWMRVCDJ-UHFFFAOYSA-N 0.000 description 3
- ZXIATBNUWJBBGT-JXOAFFINSA-N 5-methoxyuridine Chemical group O=C1NC(=O)C(OC)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 ZXIATBNUWJBBGT-JXOAFFINSA-N 0.000 description 3
- 239000013607 AAV vector Substances 0.000 description 3
- 102000012758 APOBEC-1 Deaminase Human genes 0.000 description 3
- 108010079649 APOBEC-1 Deaminase Proteins 0.000 description 3
- 102100036664 Adenosine deaminase Human genes 0.000 description 3
- 108091032955 Bacterial small RNA Proteins 0.000 description 3
- 108020004635 Complementary DNA Proteins 0.000 description 3
- UHDGCWIWMRVCDJ-PSQAKQOGSA-N Cytidine Natural products O=C1N=C(N)C=CN1[C@@H]1[C@@H](O)[C@@H](O)[C@H](CO)O1 UHDGCWIWMRVCDJ-PSQAKQOGSA-N 0.000 description 3
- 230000007018 DNA scission Effects 0.000 description 3
- 101000964378 Homo sapiens DNA dC->dU-editing enzyme APOBEC-3A Proteins 0.000 description 3
- 101000964385 Homo sapiens DNA dC->dU-editing enzyme APOBEC-3B Proteins 0.000 description 3
- 101000964383 Homo sapiens DNA dC->dU-editing enzyme APOBEC-3C Proteins 0.000 description 3
- 101000964382 Homo sapiens DNA dC->dU-editing enzyme APOBEC-3D Proteins 0.000 description 3
- 101000964377 Homo sapiens DNA dC->dU-editing enzyme APOBEC-3F Proteins 0.000 description 3
- 102100034349 Integrase Human genes 0.000 description 3
- 241000713666 Lentivirus Species 0.000 description 3
- 108091034117 Oligonucleotide Proteins 0.000 description 3
- 241000194020 Streptococcus thermophilus Species 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- AIYUHDOJVYHVIT-UHFFFAOYSA-M caesium chloride Chemical compound [Cl-].[Cs+] AIYUHDOJVYHVIT-UHFFFAOYSA-M 0.000 description 3
- UHDGCWIWMRVCDJ-ZAKLUEHWSA-N cytidine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O1 UHDGCWIWMRVCDJ-ZAKLUEHWSA-N 0.000 description 3
- 230000009615 deamination Effects 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 210000002242 embryoid body Anatomy 0.000 description 3
- 239000012634 fragment Substances 0.000 description 3
- 108700004026 gag Genes Proteins 0.000 description 3
- 238000001415 gene therapy Methods 0.000 description 3
- 230000000977 initiatory effect Effects 0.000 description 3
- 230000004807 localization Effects 0.000 description 3
- 239000011159 matrix material Substances 0.000 description 3
- 239000002105 nanoparticle Substances 0.000 description 3
- 210000002569 neuron Anatomy 0.000 description 3
- 239000008194 pharmaceutical composition Substances 0.000 description 3
- 108700004029 pol Genes Proteins 0.000 description 3
- 238000003762 quantitative reverse transcription PCR Methods 0.000 description 3
- 238000003753 real-time PCR Methods 0.000 description 3
- 238000010839 reverse transcription Methods 0.000 description 3
- 238000012552 review Methods 0.000 description 3
- 230000000392 somatic effect Effects 0.000 description 3
- 210000000130 stem cell Anatomy 0.000 description 3
- 241000701161 unidentified adenovirus Species 0.000 description 3
- 241001430294 unidentified retrovirus Species 0.000 description 3
- 210000002845 virion Anatomy 0.000 description 3
- LRFJOIPOPUJUMI-KWXKLSQISA-N 2-[2,2-bis[(9z,12z)-octadeca-9,12-dienyl]-1,3-dioxolan-4-yl]-n,n-dimethylethanamine Chemical compound CCCCC\C=C/C\C=C/CCCCCCCCC1(CCCCCCCC\C=C/C\C=C/CCCCC)OCC(CCN(C)C)O1 LRFJOIPOPUJUMI-KWXKLSQISA-N 0.000 description 2
- 101710169336 5'-deoxyadenosine deaminase Proteins 0.000 description 2
- 108091093088 Amplicon Proteins 0.000 description 2
- 102000018746 Apelin Human genes 0.000 description 2
- 108010052412 Apelin Proteins 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- 238000010356 CRISPR-Cas9 genome editing Methods 0.000 description 2
- AQGNHMOJWBZFQQ-UHFFFAOYSA-N CT 99021 Chemical compound CC1=CNC(C=2C(=NC(NCCNC=3N=CC(=CC=3)C#N)=NC=2)C=2C(=CC(Cl)=CC=2)Cl)=N1 AQGNHMOJWBZFQQ-UHFFFAOYSA-N 0.000 description 2
- 108010009540 DNA (Cytosine-5-)-Methyltransferase 1 Proteins 0.000 description 2
- 102100036279 DNA (cytosine-5)-methyltransferase 1 Human genes 0.000 description 2
- 102100024812 DNA (cytosine-5)-methyltransferase 3A Human genes 0.000 description 2
- 102100024810 DNA (cytosine-5)-methyltransferase 3B Human genes 0.000 description 2
- 102100040263 DNA dC->dU-editing enzyme APOBEC-3A Human genes 0.000 description 2
- 102100040262 DNA dC->dU-editing enzyme APOBEC-3B Human genes 0.000 description 2
- 102100040261 DNA dC->dU-editing enzyme APOBEC-3C Human genes 0.000 description 2
- 102100040264 DNA dC->dU-editing enzyme APOBEC-3D Human genes 0.000 description 2
- 102100040266 DNA dC->dU-editing enzyme APOBEC-3F Human genes 0.000 description 2
- 102100038076 DNA dC->dU-editing enzyme APOBEC-3G Human genes 0.000 description 2
- 102100038050 DNA dC->dU-editing enzyme APOBEC-3H Human genes 0.000 description 2
- 230000033616 DNA repair Effects 0.000 description 2
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 2
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 2
- 241000252212 Danio rerio Species 0.000 description 2
- 241000702421 Dependoparvovirus Species 0.000 description 2
- 102000004533 Endonucleases Human genes 0.000 description 2
- 108010042407 Endonucleases Proteins 0.000 description 2
- 101710091045 Envelope protein Proteins 0.000 description 2
- 101710177291 Gag polyprotein Proteins 0.000 description 2
- 108010070675 Glutathione transferase Proteins 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 102000016285 Guanine Nucleotide Exchange Factors Human genes 0.000 description 2
- 108010067218 Guanine Nucleotide Exchange Factors Proteins 0.000 description 2
- 208000031886 HIV Infections Diseases 0.000 description 2
- 102000029812 HNH nuclease Human genes 0.000 description 2
- 108060003760 HNH nuclease Proteins 0.000 description 2
- 101710154606 Hemagglutinin Proteins 0.000 description 2
- 102100029100 Hematopoietic prostaglandin D synthase Human genes 0.000 description 2
- 101000742736 Homo sapiens DNA dC->dU-editing enzyme APOBEC-3G Proteins 0.000 description 2
- 101000742769 Homo sapiens DNA dC->dU-editing enzyme APOBEC-3H Proteins 0.000 description 2
- 241000713340 Human immunodeficiency virus 2 Species 0.000 description 2
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 2
- 101710175625 Maltose/maltodextrin-binding periplasmic protein Proteins 0.000 description 2
- 206010056677 Nerve degeneration Diseases 0.000 description 2
- 108010066154 Nuclear Export Signals Proteins 0.000 description 2
- 108020004711 Nucleic Acid Probes Proteins 0.000 description 2
- 101710093908 Outer capsid protein VP4 Proteins 0.000 description 2
- 101710135467 Outer capsid protein sigma-1 Proteins 0.000 description 2
- 238000012408 PCR amplification Methods 0.000 description 2
- 229930182555 Penicillin Natural products 0.000 description 2
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 2
- 101710176177 Protein A56 Proteins 0.000 description 2
- 101710188315 Protein X Proteins 0.000 description 2
- 238000002123 RNA extraction Methods 0.000 description 2
- 102000006382 Ribonucleases Human genes 0.000 description 2
- 108010083644 Ribonucleases Proteins 0.000 description 2
- 239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 2
- 102100039988 Serine/threonine-protein kinase ULK1 Human genes 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 241000713675 Spumavirus Species 0.000 description 2
- 241000187191 Streptomyces viridochromogenes Species 0.000 description 2
- 241000203587 Streptosporangium roseum Species 0.000 description 2
- 101710172711 Structural protein Proteins 0.000 description 2
- 108700019146 Transgenes Proteins 0.000 description 2
- 239000007984 Tris EDTA buffer Substances 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 210000005006 adaptive immune system Anatomy 0.000 description 2
- 239000012491 analyte Substances 0.000 description 2
- DRTQHJPVMGBUCF-PSQAKQOGSA-N beta-L-uridine Natural products O[C@H]1[C@@H](O)[C@H](CO)O[C@@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-PSQAKQOGSA-N 0.000 description 2
- 108700023293 biotin carboxyl carrier Proteins 0.000 description 2
- 239000001506 calcium phosphate Substances 0.000 description 2
- 229910000389 calcium phosphate Inorganic materials 0.000 description 2
- 235000011010 calcium phosphates Nutrition 0.000 description 2
- 230000003197 catalytic effect Effects 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000007385 chemical modification Methods 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 239000012539 chromatography resin Substances 0.000 description 2
- 238000003776 cleavage reaction Methods 0.000 description 2
- 239000002299 complementary DNA Substances 0.000 description 2
- 239000000562 conjugate Substances 0.000 description 2
- 230000021615 conjugation Effects 0.000 description 2
- 238000000354 decomposition reaction Methods 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- 239000012636 effector Substances 0.000 description 2
- 239000003623 enhancer Substances 0.000 description 2
- 108700004025 env Genes Proteins 0.000 description 2
- 238000010195 expression analysis Methods 0.000 description 2
- 239000013613 expression plasmid Substances 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 238000000684 flow cytometry Methods 0.000 description 2
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 2
- 238000001476 gene delivery Methods 0.000 description 2
- 102000034356 gene-regulatory proteins Human genes 0.000 description 2
- 108091006104 gene-regulatory proteins Proteins 0.000 description 2
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 2
- 239000000185 hemagglutinin Substances 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 230000002779 inactivation Effects 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000035800 maturation Effects 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 2
- 208000005264 motor neuron disease Diseases 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 210000002241 neurite Anatomy 0.000 description 2
- 208000015122 neurodegenerative disease Diseases 0.000 description 2
- 230000030147 nuclear export Effects 0.000 description 2
- 239000002853 nucleic acid probe Substances 0.000 description 2
- 238000001543 one-way ANOVA Methods 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- 229940049954 penicillin Drugs 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 239000013600 plasmid vector Substances 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 230000008439 repair process Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000007017 scission Effects 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 229960005322 streptomycin Drugs 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- RWQNBRDOKXIBIV-UHFFFAOYSA-N thymine Chemical compound CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 description 2
- 238000010361 transduction Methods 0.000 description 2
- 230000026683 transduction Effects 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 238000013519 translation Methods 0.000 description 2
- 230000014616 translation Effects 0.000 description 2
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 2
- 238000011144 upstream manufacturing Methods 0.000 description 2
- 229940035893 uracil Drugs 0.000 description 2
- DRTQHJPVMGBUCF-UHFFFAOYSA-N uracil arabinoside Natural products OC1C(O)C(CO)OC1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-UHFFFAOYSA-N 0.000 description 2
- 229940045145 uridine Drugs 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- 230000035899 viability Effects 0.000 description 2
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- CKTSBUTUHBMZGZ-SHYZEUOFSA-N 2'‐deoxycytidine Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 CKTSBUTUHBMZGZ-SHYZEUOFSA-N 0.000 description 1
- JTBBWRKSUYCPFY-UHFFFAOYSA-N 2,3-dihydro-1h-pyrimidin-4-one Chemical compound O=C1NCNC=C1 JTBBWRKSUYCPFY-UHFFFAOYSA-N 0.000 description 1
- MWBWWFOAEOYUST-UHFFFAOYSA-N 2-aminopurine Chemical compound NC1=NC=C2N=CNC2=N1 MWBWWFOAEOYUST-UHFFFAOYSA-N 0.000 description 1
- VKWMGUNWDFIWNW-UHFFFAOYSA-N 2-chloro-1,1-dioxo-1,2-benzothiazol-3-one Chemical compound C1=CC=C2S(=O)(=O)N(Cl)C(=O)C2=C1 VKWMGUNWDFIWNW-UHFFFAOYSA-N 0.000 description 1
- IDDDVXIUIXWAGJ-DDSAHXNVSA-N 4-[(1r)-1-aminoethyl]-n-pyridin-4-ylcyclohexane-1-carboxamide;dihydrochloride Chemical compound Cl.Cl.C1CC([C@H](N)C)CCC1C(=O)NC1=CC=NC=C1 IDDDVXIUIXWAGJ-DDSAHXNVSA-N 0.000 description 1
- AGFIRQJZCNVMCW-UAKXSSHOSA-N 5-bromouridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(Br)=C1 AGFIRQJZCNVMCW-UAKXSSHOSA-N 0.000 description 1
- OGHAROSJZRTIOK-KQYNXXCUSA-O 7-methylguanosine Chemical compound C1=2N=C(N)NC(=O)C=2[N+](C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OGHAROSJZRTIOK-KQYNXXCUSA-O 0.000 description 1
- 108010004483 APOBEC-3G Deaminase Proteins 0.000 description 1
- 241000007910 Acaryochloris marina Species 0.000 description 1
- 241001135192 Acetohalobium arabaticum Species 0.000 description 1
- 241001464929 Acidithiobacillus caldus Species 0.000 description 1
- 241000605222 Acidithiobacillus ferrooxidans Species 0.000 description 1
- 241001655883 Adeno-associated virus - 1 Species 0.000 description 1
- 241000702423 Adeno-associated virus - 2 Species 0.000 description 1
- 241000202702 Adeno-associated virus - 3 Species 0.000 description 1
- 241000580270 Adeno-associated virus - 4 Species 0.000 description 1
- 241001634120 Adeno-associated virus - 5 Species 0.000 description 1
- 241000972680 Adeno-associated virus - 6 Species 0.000 description 1
- 241001164823 Adeno-associated virus - 7 Species 0.000 description 1
- 241001164825 Adeno-associated virus - 8 Species 0.000 description 1
- HJCMDXDYPOUFDY-WHFBIAKZSA-N Ala-Gln Chemical compound C[C@H](N)C(=O)N[C@H](C(O)=O)CCC(N)=O HJCMDXDYPOUFDY-WHFBIAKZSA-N 0.000 description 1
- 241000640374 Alicyclobacillus acidocaldarius Species 0.000 description 1
- 241000190857 Allochromatium vinosum Species 0.000 description 1
- 241001664176 Alpharetrovirus Species 0.000 description 1
- 241000147155 Ammonifex degensii Species 0.000 description 1
- 108020000948 Antisense Oligonucleotides Proteins 0.000 description 1
- 101710095342 Apolipoprotein B Proteins 0.000 description 1
- 102100040202 Apolipoprotein B-100 Human genes 0.000 description 1
- 241000620196 Arthrospira maxima Species 0.000 description 1
- 240000002900 Arthrospira platensis Species 0.000 description 1
- 235000016425 Arthrospira platensis Nutrition 0.000 description 1
- 241001495183 Arthrospira sp. Species 0.000 description 1
- 102000007370 Ataxin2 Human genes 0.000 description 1
- 108010032951 Ataxin2 Proteins 0.000 description 1
- 108010014380 Autophagy-Related Protein-1 Homolog Proteins 0.000 description 1
- 241000713826 Avian leukosis virus Species 0.000 description 1
- 239000012583 B-27 Supplement Substances 0.000 description 1
- 241000906059 Bacillus pseudomycoides Species 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 241000616876 Belliella baltica Species 0.000 description 1
- 241001231757 Betaretrovirus Species 0.000 description 1
- 241000714266 Bovine leukemia virus Species 0.000 description 1
- 241000701822 Bovine papillomavirus Species 0.000 description 1
- 102100027310 Bromodomain adjacent to zinc finger domain protein 1A Human genes 0.000 description 1
- 241000823281 Burkholderiales bacterium Species 0.000 description 1
- 101150077194 CAP1 gene Proteins 0.000 description 1
- 101150018129 CSF2 gene Proteins 0.000 description 1
- 101150069031 CSN2 gene Proteins 0.000 description 1
- 241000589875 Campylobacter jejuni Species 0.000 description 1
- 241001496650 Candidatus Desulforudis Species 0.000 description 1
- 241000713756 Caprine arthritis encephalitis virus Species 0.000 description 1
- 241000193163 Clostridioides difficile Species 0.000 description 1
- 241000193155 Clostridium botulinum Species 0.000 description 1
- 108020004705 Codon Proteins 0.000 description 1
- 241000907165 Coleofasciculus chthonoplastes Species 0.000 description 1
- 241000186216 Corynebacterium Species 0.000 description 1
- 241000918600 Corynebacterium ulcerans Species 0.000 description 1
- 241000065716 Crocosphaera watsonii Species 0.000 description 1
- 101150074775 Csf1 gene Proteins 0.000 description 1
- 241000159506 Cyanothece Species 0.000 description 1
- KDXKERNSBIXSRK-RXMQYKEDSA-N D-lysine Chemical compound NCCCC[C@@H](N)C(O)=O KDXKERNSBIXSRK-RXMQYKEDSA-N 0.000 description 1
- HMFHBZSHGGEWLO-SOOFDHNKSA-N D-ribofuranose Chemical group OC[C@H]1OC(O)[C@H](O)[C@@H]1O HMFHBZSHGGEWLO-SOOFDHNKSA-N 0.000 description 1
- DWJXYEABWRJFSP-XOBRGWDASA-N DAPT Chemical compound N([C@@H](C)C(=O)N[C@H](C(=O)OC(C)(C)C)C=1C=CC=CC=1)C(=O)CC1=CC(F)=CC(F)=C1 DWJXYEABWRJFSP-XOBRGWDASA-N 0.000 description 1
- 108050002829 DNA (cytosine-5)-methyltransferase 3A Proteins 0.000 description 1
- 101710123222 DNA (cytosine-5)-methyltransferase 3B Proteins 0.000 description 1
- 101710082737 DNA dC->dU-editing enzyme APOBEC-3H Proteins 0.000 description 1
- 230000006820 DNA synthesis Effects 0.000 description 1
- 230000004568 DNA-binding Effects 0.000 description 1
- 241001663879 Deltaretrovirus Species 0.000 description 1
- CKTSBUTUHBMZGZ-UHFFFAOYSA-N Deoxycytidine Natural products O=C1N=C(N)C=CN1C1OC(CO)C(O)C1 CKTSBUTUHBMZGZ-UHFFFAOYSA-N 0.000 description 1
- 108010053770 Deoxyribonucleases Proteins 0.000 description 1
- 102000016911 Deoxyribonucleases Human genes 0.000 description 1
- 108010016626 Dipeptides Proteins 0.000 description 1
- 102100029791 Double-stranded RNA-specific adenosine deaminase Human genes 0.000 description 1
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 101710121417 Envelope glycoprotein Proteins 0.000 description 1
- 101710191360 Eosinophil cationic protein Proteins 0.000 description 1
- 241001663878 Epsilonretrovirus Species 0.000 description 1
- 241000713730 Equine infectious anemia virus Species 0.000 description 1
- 208000031637 Erythroblastic Acute Leukemia Diseases 0.000 description 1
- 208000036566 Erythroleukaemia Diseases 0.000 description 1
- 241000326311 Exiguobacterium sibiricum Species 0.000 description 1
- 108700024394 Exon Proteins 0.000 description 1
- 241000192016 Finegoldia magna Species 0.000 description 1
- 241001663880 Gammaretrovirus Species 0.000 description 1
- 108700028146 Genetic Enhancer Elements Proteins 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 101710120828 Guanine nucleotide exchange factor C9orf72 Proteins 0.000 description 1
- 102100024489 Guanine nucleotide exchange protein SMCR8 Human genes 0.000 description 1
- 101150013707 HBB gene Proteins 0.000 description 1
- 102100027685 Hemoglobin subunit alpha Human genes 0.000 description 1
- 108091005902 Hemoglobin subunit alpha Proteins 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 101000937778 Homo sapiens Bromodomain adjacent to zinc finger domain protein 1A Proteins 0.000 description 1
- 101000964330 Homo sapiens C->U-editing enzyme APOBEC-1 Proteins 0.000 description 1
- 101100383812 Homo sapiens C9orf72 gene Proteins 0.000 description 1
- 101100220044 Homo sapiens CD34 gene Proteins 0.000 description 1
- 101000909242 Homo sapiens DNA (cytosine-5)-methyltransferase 3A Proteins 0.000 description 1
- 101000909249 Homo sapiens DNA (cytosine-5)-methyltransferase 3B Proteins 0.000 description 1
- 101000865408 Homo sapiens Double-stranded RNA-specific adenosine deaminase Proteins 0.000 description 1
- 101000689353 Homo sapiens Guanine nucleotide exchange protein SMCR8 Proteins 0.000 description 1
- 101000598921 Homo sapiens Orexin Proteins 0.000 description 1
- 101001061919 Homo sapiens Ras-related protein Rab-39B Proteins 0.000 description 1
- 101000712571 Homo sapiens Ras-related protein Rab-8A Proteins 0.000 description 1
- 101000607335 Homo sapiens Serine/threonine-protein kinase ULK1 Proteins 0.000 description 1
- 101000755690 Homo sapiens Single-stranded DNA cytosine deaminase Proteins 0.000 description 1
- 241000725303 Human immunodeficiency virus Species 0.000 description 1
- 229930010555 Inosine Natural products 0.000 description 1
- UGQMRVRMYYASKQ-KQYNXXCUSA-N Inosine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC(O)=C2N=C1 UGQMRVRMYYASKQ-KQYNXXCUSA-N 0.000 description 1
- 102100021244 Integral membrane protein GPR180 Human genes 0.000 description 1
- 108010015268 Integration Host Factors Proteins 0.000 description 1
- 108020004684 Internal Ribosome Entry Sites Proteins 0.000 description 1
- 241001430080 Ktedonobacter racemifer Species 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- 241000186673 Lactobacillus delbrueckii Species 0.000 description 1
- 241000186869 Lactobacillus salivarius Species 0.000 description 1
- 108090000364 Ligases Proteins 0.000 description 1
- 102000003960 Ligases Human genes 0.000 description 1
- 239000000232 Lipid Bilayer Substances 0.000 description 1
- 241000186805 Listeria innocua Species 0.000 description 1
- 241001134698 Lyngbya Species 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 241000501784 Marinobacter sp. Species 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241000204637 Methanohalobium evestigatum Species 0.000 description 1
- 108030004080 Methylcytosine dioxygenases Proteins 0.000 description 1
- 241000192710 Microcystis aeruginosa Species 0.000 description 1
- 241000190928 Microscilla marina Species 0.000 description 1
- 208000026072 Motor neurone disease Diseases 0.000 description 1
- 241000713333 Mouse mammary tumor virus Species 0.000 description 1
- 241000714177 Murine leukemia virus Species 0.000 description 1
- 101100245221 Mus musculus Prss8 gene Proteins 0.000 description 1
- 206010028289 Muscle atrophy Diseases 0.000 description 1
- 239000012580 N-2 Supplement Substances 0.000 description 1
- 241000167285 Natranaerobius thermophilus Species 0.000 description 1
- 241000588653 Neisseria Species 0.000 description 1
- 101100385413 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) csm-3 gene Proteins 0.000 description 1
- 241000919925 Nitrosococcus halophilus Species 0.000 description 1
- 241001515112 Nitrosococcus watsonii Species 0.000 description 1
- 241000203619 Nocardiopsis dassonvillei Species 0.000 description 1
- 241001223105 Nodularia spumigena Species 0.000 description 1
- 241000192673 Nostoc sp. Species 0.000 description 1
- 108700026244 Open Reading Frames Proteins 0.000 description 1
- 108700022034 Opsonin Proteins Proteins 0.000 description 1
- 241000192520 Oscillatoria sp. Species 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 206010033799 Paralysis Diseases 0.000 description 1
- 241000142651 Pelotomaculum thermopropionicum Species 0.000 description 1
- 241000983938 Petrotoga mobilis Species 0.000 description 1
- 241001599925 Polaromonas naphthalenivorans Species 0.000 description 1
- 241001472610 Polaromonas sp. Species 0.000 description 1
- 241001505332 Polyomavirus sp. Species 0.000 description 1
- 241001135221 Prevotella intermedia Species 0.000 description 1
- 102000001253 Protein Kinase Human genes 0.000 description 1
- 108010076504 Protein Sorting Signals Proteins 0.000 description 1
- 241000590028 Pseudoalteromonas haloplanktis Species 0.000 description 1
- 229930185560 Pseudouridine Natural products 0.000 description 1
- PTJWIQPHWPFNBW-UHFFFAOYSA-N Pseudouridine C Natural products OC1C(O)C(CO)OC1C1=CNC(=O)NC1=O PTJWIQPHWPFNBW-UHFFFAOYSA-N 0.000 description 1
- 241001647888 Psychroflexus Species 0.000 description 1
- 102000014450 RNA Polymerase III Human genes 0.000 description 1
- 108010078067 RNA Polymerase III Proteins 0.000 description 1
- 230000006819 RNA synthesis Effects 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 102100029547 Ras-related protein Rab-39B Human genes 0.000 description 1
- 102100033480 Ras-related protein Rab-8A Human genes 0.000 description 1
- 101100047461 Rattus norvegicus Trpm8 gene Proteins 0.000 description 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
- 108091081062 Repeated sequence (DNA) Proteins 0.000 description 1
- 102100036007 Ribonuclease 3 Human genes 0.000 description 1
- 101710192197 Ribonuclease 3 Proteins 0.000 description 1
- 102000003661 Ribonuclease III Human genes 0.000 description 1
- 108010057163 Ribonuclease III Proteins 0.000 description 1
- 108091028664 Ribonucleotide Proteins 0.000 description 1
- PYMYPHUHKUWMLA-LMVFSUKVSA-N Ribose Natural products OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-LMVFSUKVSA-N 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 206010039491 Sarcoma Diseases 0.000 description 1
- 241001606419 Spiroplasma syrphidicola Species 0.000 description 1
- 241000203029 Spiroplasma taiwanense Species 0.000 description 1
- 241000194056 Streptococcus iniae Species 0.000 description 1
- 241000194022 Streptococcus sp. Species 0.000 description 1
- 241001518258 Streptomyces pristinaespiralis Species 0.000 description 1
- 241000192560 Synechococcus sp. Species 0.000 description 1
- 208000012827 T-B+ severe combined immunodeficiency due to gamma chain deficiency Diseases 0.000 description 1
- 241000206213 Thermosipho africanus Species 0.000 description 1
- RYYWUUFWQRZTIU-UHFFFAOYSA-N Thiophosphoric acid Chemical group OP(O)(S)=O RYYWUUFWQRZTIU-UHFFFAOYSA-N 0.000 description 1
- 108091036066 Three prime untranslated region Proteins 0.000 description 1
- 108700009124 Transcription Initiation Site Proteins 0.000 description 1
- 241000078013 Trichormus variabilis Species 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 108700031758 U1A Proteins 0.000 description 1
- 108091023045 Untranslated Region Proteins 0.000 description 1
- 241000700618 Vaccinia virus Species 0.000 description 1
- 108700005077 Viral Genes Proteins 0.000 description 1
- 108010087302 Viral Structural Proteins Proteins 0.000 description 1
- 208000010094 Visna Diseases 0.000 description 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
- 108010031318 Vitronectin Proteins 0.000 description 1
- 102100035140 Vitronectin Human genes 0.000 description 1
- 201000007146 X-linked severe combined immunodeficiency Diseases 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 241001673106 [Bacillus] selenitireducens Species 0.000 description 1
- 108010076089 accutase Proteins 0.000 description 1
- 230000021736 acetylation Effects 0.000 description 1
- 238000006640 acetylation reaction Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 208000021841 acute erythroid leukemia Diseases 0.000 description 1
- 230000003044 adaptive effect Effects 0.000 description 1
- 101150063416 add gene Proteins 0.000 description 1
- 239000012574 advanced DMEM Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- HMFHBZSHGGEWLO-UHFFFAOYSA-N alpha-D-Furanose-Ribose Natural products OCC1OC(O)C(O)C1O HMFHBZSHGGEWLO-UHFFFAOYSA-N 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 125000003368 amide group Chemical group 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 239000000074 antisense oligonucleotide Substances 0.000 description 1
- 238000012230 antisense oligonucleotides Methods 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 229940011019 arthrospira platensis Drugs 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 210000001130 astrocyte Anatomy 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 230000004642 autophagic pathway Effects 0.000 description 1
- 210000004957 autophagosome Anatomy 0.000 description 1
- 230000008970 bacterial immunity Effects 0.000 description 1
- 230000003542 behavioural effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- WGDUUQDYDIIBKT-UHFFFAOYSA-N beta-Pseudouridine Natural products OC1OC(CN2C=CC(=O)NC2=O)C(O)C1O WGDUUQDYDIIBKT-UHFFFAOYSA-N 0.000 description 1
- 229920002988 biodegradable polymer Polymers 0.000 description 1
- 239000004621 biodegradable polymer Substances 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N biotin Natural products N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 238000006664 bond formation reaction Methods 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 210000000133 brain stem Anatomy 0.000 description 1
- 238000010804 cDNA synthesis Methods 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 150000004649 carbonic acid derivatives Chemical class 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000034303 cell budding Effects 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 239000006143 cell culture medium Substances 0.000 description 1
- 108091092356 cellular DNA Proteins 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 238000004891 communication Methods 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000011340 continuous therapy Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 101150055601 cops2 gene Proteins 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 238000011461 current therapy Methods 0.000 description 1
- 230000002559 cytogenic effect Effects 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 230000007711 cytoplasmic localization Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000009795 derivation Methods 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 206010013023 diphtheria Diseases 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 229940115080 doxil Drugs 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 238000007877 drug screening Methods 0.000 description 1
- 238000011977 dual antiplatelet therapy Methods 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 230000012202 endocytosis Effects 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 150000002170 ethers Chemical class 0.000 description 1
- VYSYZMNJHYOXGN-UHFFFAOYSA-N ethyl n-aminocarbamate Chemical compound CCOC(=O)NN VYSYZMNJHYOXGN-UHFFFAOYSA-N 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000006846 excision repair Effects 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 239000012091 fetal bovine serum Substances 0.000 description 1
- 239000012894 fetal calf serum Substances 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 108700010758 gag-pro Proteins 0.000 description 1
- 101150081889 gag-pro gene Proteins 0.000 description 1
- 108700010759 gag-pro-pol Proteins 0.000 description 1
- 101150061559 gag-pro-pol gene Proteins 0.000 description 1
- 238000012239 gene modification Methods 0.000 description 1
- 230000030279 gene silencing Effects 0.000 description 1
- 238000012226 gene silencing method Methods 0.000 description 1
- 238000007429 general method Methods 0.000 description 1
- 230000005017 genetic modification Effects 0.000 description 1
- 235000013617 genetically modified food Nutrition 0.000 description 1
- 125000000291 glutamic acid group Chemical group N[C@@H](CCC(O)=O)C(=O)* 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 230000013595 glycosylation Effects 0.000 description 1
- 238000006206 glycosylation reaction Methods 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 102000046390 human APOBEC1 Human genes 0.000 description 1
- 102000048646 human APOBEC3A Human genes 0.000 description 1
- 102000048415 human APOBEC3B Human genes 0.000 description 1
- 102000048419 human APOBEC3C Human genes 0.000 description 1
- 102000043429 human APOBEC3D Human genes 0.000 description 1
- 102000049338 human APOBEC3F Human genes 0.000 description 1
- 102000054962 human APOBEC3G Human genes 0.000 description 1
- 102000044839 human APOBEC3H Human genes 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 230000003301 hydrolyzing effect Effects 0.000 description 1
- 230000033444 hydroxylation Effects 0.000 description 1
- 238000005805 hydroxylation reaction Methods 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000008676 import Effects 0.000 description 1
- 230000000415 inactivating effect Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 238000011221 initial treatment Methods 0.000 description 1
- 150000002485 inorganic esters Chemical class 0.000 description 1
- 229960003786 inosine Drugs 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 238000005304 joining Methods 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 238000011005 laboratory method Methods 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 230000029226 lipidation Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000010859 live-cell imaging Methods 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 230000002934 lysing effect Effects 0.000 description 1
- 230000017156 mRNA modification Effects 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 231100000324 minimal toxicity Toxicity 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 210000000663 muscle cell Anatomy 0.000 description 1
- 230000003387 muscular Effects 0.000 description 1
- 201000000585 muscular atrophy Diseases 0.000 description 1
- MAFHEURJBRFHIT-YEUCEMRASA-N n,n-dimethyl-1,2-bis[(z)-octadec-9-enoxy]propan-1-amine Chemical compound CCCCCCCC\C=C/CCCCCCCCOC(C)C(N(C)C)OCCCCCCCC\C=C/CCCCCCCC MAFHEURJBRFHIT-YEUCEMRASA-N 0.000 description 1
- NFQBIAXADRDUGK-KWXKLSQISA-N n,n-dimethyl-2,3-bis[(9z,12z)-octadeca-9,12-dienoxy]propan-1-amine Chemical compound CCCCC\C=C/C\C=C/CCCCCCCCOCC(CN(C)C)OCCCCCCCC\C=C/C\C=C/CCCCC NFQBIAXADRDUGK-KWXKLSQISA-N 0.000 description 1
- GLGLUQVVDHRLQK-WRBBJXAJSA-N n,n-dimethyl-2,3-bis[(z)-octadec-9-enoxy]propan-1-amine Chemical compound CCCCCCCC\C=C/CCCCCCCCOCC(CN(C)C)OCCCCCCCC\C=C/CCCCCCCC GLGLUQVVDHRLQK-WRBBJXAJSA-N 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 210000004498 neuroglial cell Anatomy 0.000 description 1
- 230000016273 neuron death Effects 0.000 description 1
- 230000006764 neuronal dysfunction Effects 0.000 description 1
- 230000007171 neuropathology Effects 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 230000012223 nuclear import Effects 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 230000030648 nucleus localization Effects 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 150000002895 organic esters Chemical class 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000003950 pathogenic mechanism Effects 0.000 description 1
- 230000007918 pathogenicity Effects 0.000 description 1
- 230000006320 pegylation Effects 0.000 description 1
- 239000000863 peptide conjugate Substances 0.000 description 1
- 239000000816 peptidomimetic Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical group [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Chemical group 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical group [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 1
- 108010089520 pol Gene Products Proteins 0.000 description 1
- 230000008488 polyadenylation Effects 0.000 description 1
- 108010040003 polyglutamine Proteins 0.000 description 1
- 229920002704 polyhistidine Polymers 0.000 description 1
- 210000000063 presynaptic terminal Anatomy 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 210000000976 primary motor cortex Anatomy 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 210000001236 prokaryotic cell Anatomy 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- XJMOSONTPMZWPB-UHFFFAOYSA-M propidium iodide Chemical compound [I-].[I-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CCC[N+](C)(CC)CC)=C1C1=CC=CC=C1 XJMOSONTPMZWPB-UHFFFAOYSA-M 0.000 description 1
- 108060006633 protein kinase Proteins 0.000 description 1
- PTJWIQPHWPFNBW-GBNDHIKLSA-N pseudouridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1C1=CNC(=O)NC1=O PTJWIQPHWPFNBW-GBNDHIKLSA-N 0.000 description 1
- 210000002804 pyramidal tract Anatomy 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 230000008707 rearrangement Effects 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000006722 reduction reaction Methods 0.000 description 1
- 230000002940 repellent Effects 0.000 description 1
- 239000005871 repellent Substances 0.000 description 1
- 230000003362 replicative effect Effects 0.000 description 1
- 230000002629 repopulating effect Effects 0.000 description 1
- 108700004030 rev Genes Proteins 0.000 description 1
- 239000002336 ribonucleotide Substances 0.000 description 1
- 125000002652 ribonucleotide group Chemical group 0.000 description 1
- 238000002864 sequence alignment Methods 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 229940126586 small molecule drug Drugs 0.000 description 1
- 238000005063 solubilization Methods 0.000 description 1
- 230000007928 solubilization Effects 0.000 description 1
- 210000000278 spinal cord Anatomy 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 229940113082 thymine Drugs 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000005030 transcription termination Effects 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 230000005945 translocation Effects 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 241001529453 unidentified herpesvirus Species 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 229940045997 vitamin a Drugs 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
- 210000005253 yeast cell Anatomy 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
- C12N9/22—Ribonucleases RNAses, DNAses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPRs]
Definitions
- ALS Amyotrophic Lateral Sclerosis
- ALS is the most prevalent adult-onset motor neuron disease with an estimated prevalence of 8/100,000 and 1,500 new cases per year in France. ALS is caused by multiple genetic causes; the most prevalent is a repeat expansion in the C9orf72 gene ( Figure 1).
- C9orf72 repeat expansions are recognized as a major genetic cause for a related neurodegenerative disorder, Frontotemporal Dementia (FTD).
- FTD Frontotemporal Dementia
- toxic gain of function of the repeats is considered to be an important pathogenic mechanism
- significantly reduced levels of C9orf72 transcript and protein have been consistently described in ALS patients indicating that C9orf72 loss of function causes neurodegeneration (Ciura, Sorana, et al. "Loss of function of C9orf72 causes motor deficits in a zebrafish model of amyotrophic lateral sclerosis.” Annals of neurology 74.2 (2013): 180-187). Therefore, restoring C9orf72 function represents an important therapeutic target in ALS, FTD and related disorders.
- ALS is untreatable through common pharmacological approaches.
- Current therapies for ALS include the administration of antisense oligonucleotides and gene silencing by AAV to target the RNA repeats transcribed from the C9orf72 gene (reviewed in Cappella, Marisa, et al. "Gene therapy for ALS—a perspective.” International journal of molecular sciences 20.18 (2019): 4388).
- these strategies remain either temporary and need replenishing as in the case of oligonucleotides or are still undergoing early clinical trials for gene delivery via the AAV approach. Therefore, there is a strong rationale for developing novel, definitive and universal strategies for this disease.
- CRISPR-system-based cytosine and adenine base editors can make pinpoint changes in the DNA with little or no double-strand break (DSB) generation (Rees, Holly A., and David R. Liu. “Base editing: precision chemistry on the genome and transcriptome of living cells.” Nature reviews genetics 19.12 (2016): 770-788).
- BEs The basic components of BEs are a catalytically disabled Cas9 nuclease, a guide RNA that drives the system to a specific DNA target, and a deaminase that produces C-G to T-A or A-T to G-C conversions (for CBEs and ABEs, respectively).
- Base-editing approaches allow precise DNA repair virtually in the absence of DSBs, and thus eliminate the risks of DSB-induced apoptosis, translocations and insertions or deletions of large portions of DNA (Kosicki, Michael, Kärt Tomberg, and Allan Bradley.
- the major objective of the present invention is to develop safe, effective and definitive therapeutic strategies for ALS through the innovative approach of base editing.
- the inventors have identified a unique site of RNA Polymerase II pause site in the promoter region of C9orf72. Their approach was therefore to mutate this site using the base editing technology to increase C9orf72 transcription and expression. Therefore, base editing approaches that target the RNA Polymerase II pause site should boost the expression of C9orf72 as well as likely reduce the toxicity due to repeat expression, thus doubling the therapeutic potential of the genome editing strategy.
- the polymer may be linear or branched, it may comprise modified amino acids, and it may be interrupted by non-amino acids.
- the terms also encompass an amino acid polymer that has been modified; for example, disulfide bond formation, glycosylation, lipidation, acetylation, phosphorylation, pegylation, or any other manipulation, such as conjugation with a labeling component.
- amino acid includes natural and/or unnatural or synthetic amino acids, including glycine and both the D or L optical isomers, and amino acid analogs and peptidomimetics.
- nucleic acid molecule or “polynucleotide” refers to a DNA molecule (for example, but not limited to, a cDNA or genomic DNA).
- the nucleic acid molecule can be single-stranded or double-stranded.
- isolated when referring to nucleic acid molecules or polypeptides means that the nucleic acid molecule or the polypeptide is substantially free from at least one other component with which it is associated or found together in nature.
- complementarity refers to the ability of a nucleic acid to form hydrogen bond(s) with another nucleic acid sequence by either traditional Watson-Crick base- pairing or other non-traditional types.
- a percent complementarity indicates the percentage of residues in a nucleic acid molecule which can form hydrogen bonds (e.g., Watson-Crick base pairing) with a second nucleic acid sequence (e.g., 5, 6, 7, 8, 9, 10 out of 10 being 50%, 60%, 70%, 80%, 90%, and 100% complementary).
- Perfectly complementary means that all the contiguous residues of a nucleic acid sequence will hydrogen bond with the same number of contiguous residues in a second nucleic acid sequence.
- “Substantially complementary” as used herein refers to a degree of complementarity that is at least 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 97%, 98%, 99%, or 100% over a region of 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 30, 35, 40, 45, 50, or more nucleotides, or refers to two nucleic acids that hybridize under stringent conditions.
- stringent conditions for hybridization refer to conditions under which a nucleic acid having complementarity to a target sequence predominantly hybridizes with the target sequence, and substantially does not hybridize to non-target sequences. Stringent conditions are generally sequence-dependent, and vary depending on a number of factors.
- hybridization or “hybridizing” refers to a process where completely or partially complementary nucleic acid strands come together under specified hybridization conditions to form a double-stranded structure or region in which the two constituent strands are joined by hydrogen bonds.
- fusion polypeptide or “fusion protein” means a protein created by joining two or more polypeptide sequences together.
- the fusion polypeptides encompassed in this invention include translation products of a chimeric gene construct that joins the nucleic acid sequences encoding a first polypeptide, e.g., an RNA-binding domain, with the nucleic acid sequence encoding a second polypeptide, e.g., an effector domain, to form a single open- reading frame.
- a “fusion polypeptide” or “fusion protein” is a recombinant protein of two or more proteins which are joined by a peptide bond or via several peptides.
- the fusion protein may also comprise a peptide linker between the two domains.
- wild type is a term of the art understood by skilled persons and means the typical form of an organism, strain, gene or characteristic as it occurs in nature as distinguished from mutant or variant forms.
- derived from refers to a process whereby a first component (e.g., a first molecule), or information from that first component, is used to isolate, derive or make a different second component (e.g., a second molecule that is different from the first).
- the comparison of sequences and determination of percent identity between two sequences can be accomplished using a mathematical algorithm, as described below.
- the percent identity between two amino acid sequences can be determined using the Needleman and Wunsch algorithm (Needleman, Saul B. & Wunsch, Christian D. (1970). "A general method applicable to the search for similarities in the amino acid sequence of two proteins". Journal of Molecular Biology.48 (3): 443–53).
- the percent identity between two nucleotide or amino acid sequences may also be determined using for example algorithms such as EMBOSS Needle (pair wise alignment; available at www.ebi.ac.uk).
- EMBOSS Needle may be used with a BLOSUM62 matrix, a “gap open penalty” of 10, a “gap extend penalty” of 0.5, a false “end gap penalty”, an “end gap open penalty” of 10 and an “end gap extend penalty” of 0.5.
- the “percent identity” is a function of the number of matching positions divided by the number of positions compared and multiplied by 100. For instance, if 6 out of 10 sequence positions are identical between the two compared sequences after alignment, then the identity is 60%.
- % identity is typically determined over the whole length of the query sequence on which the analysis is performed.
- Two molecules having the same primary amino acid sequence or nucleic acid sequence are identical irrespective of any chemical and/or biological modification.
- a first amino acid sequence having at least 90% of identity with a second amino acid sequence means that the first sequence has 90; 91; 92; 93; 94; 95; 96; 97; 98; 99 or 100% of identity with the second amino acid sequence.
- linker refers to any means, entity or moiety used to join two or more entities.
- a linker can be a covalent linker or a non-covalent linker.
- covalent linkers include covalent bonds or a linker moiety covalently attached to one or more of the proteins or domains to be linked.
- the linker can also be a non-covalent bond, e.g., an organometallic bond through a metal centre such as platinum atom.
- various functionalities can be used, such as amide groups, including carbonic acid derivatives, ethers, esters, including organic and inorganic esters, amino, urethane, urea and the like.
- the domains can be modified by oxidation, hydroxylation, substitution, reduction etc. to provide a site for coupling. Methods for conjugation are well known by persons skilled in the art and are encompassed for use in the present invention.
- Linker moieties include, but are not limited to, chemical linker moieties, or for example a peptide linker moiety (a linker sequence). It will be appreciated that modification which do not significantly decrease the function of the RNA- binding domain and effector domain are preferred.
- the “linked” as used herein refers to the attachment of two or more entities to form one entity.
- a conjugate encompasses both peptide-small molecule conjugates as well as peptide-protein/peptide conjugates.
- the term “base-editing enzyme” refers to fusion protein comprising a defective CRISPR/Cas nuclease linked to a deaminase polypeptide. The term is also known as “base- editor”.
- CBEs cytosine base-editing enzymes
- ABEs adenine base-editing enzymes
- cytosine base-editing enzymes are created by fusing the defective CRISPR/Cas nuclease to a deaminase.
- the term “deaminase” refers to an enzyme that catalyzes a deamination reaction.
- deamination refers to the removal of an amine group from one molecule.
- the deaminase is a cytidine deaminase, catalysing the hydrolytic deamination of cytidine or deoxycytidine to uracil or deoxyuracil, respectively.
- nuclease includes a protein (i.e.
- CRISPR/Cas nuclease has its general meaning in the art and refers to segments of prokaryotic DNA containing clustered regularly interspaced short palindromic repeats (CRISPR) and associated nucleases encoded by Cas genes.
- CRISPR clustered regularly interspaced short palindromic repeats
- the CRISPR/Cas loci encode RNA-guided adaptive immune systems against mobile genetic elements (viruses, transposable elements and conjugative plasmids). Three types of CRISPR systems have been identified.
- CRISPR clusters contain spacers, the sequences complementary to antecedent mobile elements. CRISPR clusters are transcribed and processed into mature CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats) RNA (crRNA).
- the CRISPR/Cas nucleases Cas9 and Cpf1 belong to the type II and type V CRISPR/Cas system and have strong endonuclease activity to cut target DNA. Cas9 is guided by a mature crRNA that contains about 20 nucleotides of unique target sequence (called spacer) and a trans-activating small RNA (tracrRNA) that also serves as a guide for ribonuclease III-aided processing of pre-crRNA.
- spacer a mature crRNA that contains about 20 nucleotides of unique target sequence
- tracrRNA trans-activating small RNA
- the crRNA:tracrRNA duplex directs Cas9 to target DNA via complementary base pairing between the spacer on the crRNA and the complementary sequence (called protospacer) on the target DNA.
- Cas9 recognizes a trinucleotide (NGG for S. Pyogenes Cas9) protospacer adjacent motif (PAM) to specify the cut site (the 3 rd or the 4 th nucleotide upstream from PAM).
- NVG trinucleotide
- PAM protospacer adjacent motif
- Cas9 or “Cas9 nuclease” refers to an RNA-guided nuclease comprising a Cas9 protein, or a fragment thereof (e.g., a protein comprising an active or inactive DNA cleavage domain of Cas9, and/or the gRNA binding domain of Cas9).
- a Cas9 nuclease is also referred to sometimes as a casn1 nuclease or a CRISPR (clustered regularly interspaced short palindromic repeat)-associated nuclease.
- CRISPR is an adaptive immune system that provides protection against mobile genetic elements (viruses, transposable elements and conjugative plasmids).
- CRISPR clusters contain spacers, sequences complementary to antecedent mobile elements, and target invading nucleic acids. CRISPR clusters are transcribed and processed into CRISPR RNA (crRNA). In type II CRISPR systems correct processing of pre-crRNA requires a trans-encoded small RNA (tracrRNA), endogenous ribonuclease 3 (rnc) and a Cas9 protein. The tracrRNA serves as a guide for ribonuclease 3-aided processing of pre- crRNA. Subsequently, Cas9/crRNA/tracrRNA endonucleolytically cleaves linear or circular dsDNA target complementary to the spacer.
- tracrRNA trans-encoded small RNA
- rnc endogenous ribonuclease 3
- Cas9 protein serves as a guide for ribonuclease 3-aided processing of pre- crRNA.
- RNA single guide RNAs
- sgRNA single guide RNAs
- gNRA single guide RNAs
- Cas9 recognizes a short motif in the CRISPR repeat sequences (the PAM or protospacer adjacent motif) to help distinguish self versus non-self.
- Cas9 nuclease sequences and structures are well known to those of skill in the art (see, e.g., “Complete genome sequence of an M1 strain of Streptococcus pyogenes.” Ferretti et al., J. J., McShan W. M., Ajdic D. J., Savic D. J., Savic G., Lyon K., Primeaux C., Sezate S., Suvorov A. N., Kenton S., Lai H. S., Lin S. P., Qian Y., Jia H.
- Cas9 nucleases and sequences include Cas9 sequences from the organisms and loci disclosed in Chylinski, Rhun, and Charpentier, “The tracrRNA and Cas9 families of type II CRISPR-Cas immunity systems” (2013) RNA Biology 10:5, 726-737; the entire contents of which are incorporated herein by reference.
- Cas9 refers to Cas9 from: Corynebacterium ulcerans (NCBI Refs: NC_015683.1, NC_017317.1); Corynebacterium diphtheria (NCBI Refs: NC_016782.1, NC_016786.1); Spiroplasma syrphidicola (NCBI Ref: NC_021284.1); Prevotella intermedia (NCBI Ref: NC_017861.1); Spiroplasma taiwanense (NCBI Ref: NC_021846.1); Streptococcus iniae (NCBI Ref: NC_021314.1); Belliella baltica (NCBI Ref: NC_018010.1); Psychroflexus torquisI (NCBI Ref: NC_018721.1); Streptococcus thermophilus (NCBI Ref: YP_820832.1); Listeria innocua (NCBI Ref: NP_472073.1);
- Cas9 nuclease comprises the amino acid sequence as set forth in SEQ ID NO: 1.
- SEQ ID NO:1 Cas9 sequence MDKKYSIGLAIGTNSVGWAVITDEYKVPSKKFKVLGNTDRHSIKKNLIGALLFDSGETAEATRLKRTAR RRYTRRKNRICYLQEIFSNEMAKVDDSFFHRLEESFLVEEDKKHERHPIFGNIVDEVAYHEKYPTIYHL RKKLVDSTDKADLRLIYLALAHMIKFRGHFLIEGDLNPDNSDVDKLFIQLVQTYNQLFEENPINASGVD AKAILSARLSKSRRLENLIAQLPGEKKNGLFGNLIALSLGLTPNFKSNFDLAEDAKLQLSKDTYDDDLD NLLAQIGDQYADLFLAAKNLSDAILLSDILRVNTEITKAPLSASMIKRYDEHHQDLTLLKALVRQQQ
- nickase has its general meaning in the art and refers to an endonuclease which cleaves only a single strand of a DNA duplex. Accordingly, the term “Cas9 nickase” refers to a nickase derived from a Cas9 protein, typically by inactivating one nuclease domain of Cas9 protein.
- guide RNA molecule generally refers to an RNA molecule (or a group of RNA molecules collectively) that can bind to a Cas9 protein and target the Cas9 protein to a specific location within a target DNA.
- a guide RNA can comprise two segments: a DNA-targeting guide segment and a protein-binding segment.
- the DNA-targeting segment comprises a nucleotide sequence that is complementary to (or at least can hybridize to under stringent conditions) a target sequence.
- the protein-binding segment interacts with a CRISPR protein, such as a Cas9 or Cas9 related polypeptide. These two segments can be located in the same RNA molecule or in two or more separate RNA molecules. When the two segments are in separate RNA molecules, the molecule comprising the DNA-targeting guide segment is sometimes referred to as the CRISPR RNA (crRNA), while the molecule comprising the protein-binding segment is referred to as the trans-activating RNA (tracrRNA).
- CRISPR RNA CRISPR RNA
- tracrRNA trans-activating RNA
- target nucleic acid refers to a nucleic acid containing a target nucleic acid sequence.
- a target nucleic acid may be single-stranded or double-stranded, and often is double-stranded DNA.
- a “target nucleic acid sequence,” “target sequence” or “target region,” as used herein, means a specific sequence or the complement thereof that one wishes to bind to using the CRISPR system as disclosed herein.
- target nucleic acid strand refers to a strand of a target nucleic acid that is subject to base-pairing with a guide RNA as disclosed herein.
- each strand can be a “target nucleic acid strand” to design crRNA and guide RNAs and used to practice the method of this invention as long as there is a suitable PAM site.
- the term “mutation” has its general meaning in the art and refers to a substitution, deletion or insertion.
- substitution means that a specific amino acid residue at a specific position is removed and another amino acid residue is inserted into the same position.
- deletion means that a specific amino acid residue is removed.
- insertion means that one or more amino acid residues are inserted before or after a specific amino acid residue.
- mutagenesis refers to the introduction of mutations into a polynucleotide sequence. According to the present invention mutations are introduced into a target DNA molecule encoding for a variant domain of the antibody so as to mimic somatic hypermutation.
- variant refers to a first composition (e.g., a first molecule), that is related to a second composition (e.g., a second molecule, also termed a “parent” molecule).
- the variant molecule can be derived from, isolated from, based on or homologous to the parent molecule.
- a variant molecule can have entire sequence identity with the original parent molecule, or alternatively, can have less than 100% sequence identity with the parent molecule.
- a variant of a sequence can be a second sequence that is at least 50; 51; 52; 53; 54; 55; 56; 57; 58; 59; 60; 61; 62; 63; 64; 65; 66; 67; 68; 69; 70; 71; 72; 73; 74; 75; 76; 77; 78; 79; 80; 81; 82; 83; 84; 85; 86; 87; 88; 89; 90; 91; 92; 93; 94; 95; 96; 97; 98; 99; 100% identical in sequence compare to the original sequence.
- Sequence identity is frequently measured in terms of percentage identity (or similarity or homology); the higher the percentage, the more similar are the two sequences.
- Methods of alignment of sequences for comparison are well known in the art. Various programs and alignment algorithms are described in: Smith and Waterman, Adv. Appl. Math., 2:482, 1981; Needleman and Wunsch, J. Mol. Biol., 48:443, 1970; Pearson and Lipman, Proc. Natl. Acad. Sci. U.S.A., 85:2444, 1988; Higgins and Sharp, Gene, 73:237-244, 1988; Higgins and Sharp, CABIOS, 5:151-153, 1989; Corpet et al. Nuc.
- ALIGN compares entire sequences against one another, while LFASTA compares regions of local similarity.
- these alignment tools and their respective tutorials are available on the Internet at the NCSA Website, for instance.
- the Blast 2 sequences function can be employed using the default BLOSUM62 matrix set to default parameters, (gap existence cost of 11, and a per residue gap cost of 1).
- the alignment should be performed using the Blast 2 sequences function, employing the PAM30 matrix set to default parameters (open gap 9, extension gap 1 penalties).
- the BLAST sequence comparison system is available, for instance, from the NCBI web site; see also Altschul et al., J. Mol.
- C9orf72 has its general meaning in the art and refers to the chromosome 9 open reading frame 72 protein that is encoded by the gene C9orf72 (Gene ID: 203228).
- the human C9orf72 gene is located on the short (p) arm of chromosome 9 open reading frame 72, from base pair 27,546,546 to base pair 27,573,866 (GRCh38). Its cytogenetic location is at 9p21.2. The protein is found in many regions of the brain, in the cytoplasm of neurons as well as in presynaptic terminals.
- C9orf72 is a component of the C9orf72-SMCR8 complex that has guanine nucleotide exchange factor (GEF) activity and regulates autophagy.
- GEF guanine nucleotide exchange factor
- C9orf72 and SMCR8 probably constitute the catalytic subunits that promote the exchange of GDP to GTP, converting inactive GDP-bound RAB8A and RAB39B into their active GTP-bound form, thereby promoting autophagosome maturation.
- the C9orf72-SMCR8 complex also acts as a regulator of autophagy initiation by interacting with the ULK1/ATG1 kinase complex and modulating its protein kinase activity.
- An exemplary amino acid sequence for C9orf72 is represented by SEQ ID NO:2.
- the identified mutation of C9ORF72 is a hexanucleotide repeat expansion of the six-letter string of nucleotides GGGGCC (Bigio EH (December 2011).
- C9ORF72 the new gene on the block, causes C9FTD/ALS: new insights provided by neuropathology. Acta Neuropathologica. 122 (6): 653–5).
- the mutation is the most common identified mutation associated with frontotemporal dementia (FTD) and amyotrophic lateral sclerosis (ALS) (Babi ⁇ Leko M, ⁇ upunski V, Kirincich J, Smilovi ⁇ D, Hortobágyi T, Hof PR, ⁇ imi ⁇ G (2019).
- FDD frontotemporal dementia
- ALS amyotrophic lateral sclerosis
- RNA Pol II pausing is a key regulatory step in transcription. RNA Pol II pauses at GC-rich regions, and almost 65% of the pause sites are cytosines (Watts, Jason A., et al. "Cis elements that mediate RNA polymerase II pausing regulate human gene expression.” The American Journal of Human Genetics 105.4 (2019): 677-688). Gene expression analysis showed that genes with more paused polymerases have lower expression levels. Therefore, mutagenesis of the pause sites might lead to a significant increase in transcription.
- pause site is located on chr9:27563356-27563366 region, is defined by the nucleotide sequence SEQ ID NO:3 (GTTCGGCTGCCGGGAAGAGGCGCGGGTAGAAGCGGGGGCTCTCCTCAGAGCT) and is depicted in Figure 1.
- ALS Amyotrophic Lateral Sclerosis
- SEQ ID NO: 29 Amyotrophic Lateral Sclerosis
- ALS has its general meaning in the art and refers to a neurodegenerative disease characterized by progressive muscular paralysis reflecting degeneration of motor neurons in the primary motor cortex, corticospinal tracts, brainstem and spinal cord. According to the present invention, ALS is caused by the C9orf72 mutation as described above.
- treatment refers to both prophylactic or preventive treatment as well as curative or disease modifying treatment, including treatment of patient at risk of contracting the disease or suspected to have contracted the disease as well as patients who are ill or have been diagnosed as suffering from a disease or medical condition, and includes suppression of clinical relapse.
- the treatment may be administered to a subject having a medical disorder or who ultimately may acquire the disorder, in order to prevent, cure, delay the onset of, reduce the severity of, or ameliorate one or more symptoms of a disorder or recurring disorder, or in order to prolong the survival of a subject beyond that expected in the absence of such treatment.
- therapeutic regimen is meant the pattern of treatment of an illness, e.g., the pattern of dosing used during therapy.
- a therapeutic regimen may include an induction regimen and a maintenance regimen.
- the phrase “induction regimen” or “induction period” refers to a therapeutic regimen (or the portion of a therapeutic regimen) that is used for the initial treatment of a disease.
- the general goal of an induction regimen is to provide a high level of drug to a patient during the initial period of a treatment regimen.
- An induction regimen may employ (in part or in whole) a "loading regimen", which may include administering a greater dose of the drug than a physician would employ during a maintenance regimen, administering a drug more frequently than a physician would administer the drug during a maintenance regimen, or both.
- maintenance regimen refers to a therapeutic regimen (or the portion of a therapeutic regimen) that is used for the maintenance of a patient during treatment of an illness, e.g., to keep the patient in remission for long periods of time (months or years).
- a maintenance regimen may employ continuous therapy (e.g., administering a drug at regular intervals, e.g., weekly, monthly, yearly, etc.) or intermittent therapy (e.g., interrupted treatment, intermittent treatment, treatment at relapse, or treatment upon achievement of a particular predetermined criteria [e.g., pain, disease manifestation, etc.]).
- the expression "therapeutically effective amount” means a sufficient amount of the active ingredient for treating or reducing the symptoms at reasonable benefit/risk ratio applicable to any medical treatment. It will be understood that the total daily usage of the compounds and compositions of the present invention will be decided by the attending physician within the scope of sound medical judgment.
- the specific therapeutically effective dose level for any particular subject will depend upon a variety of factors including the disorder being treated and the severity of the disorder; activity of the specific compound employed; the specific composition employed, the age, body weight, general health, sex and diet of the subject; the time of administration, route of administration, and rate of excretion of the specific compound employed; the duration of the treatment; drugs used in combination with the active ingredients; and like factors well known in the medical arts.
- the first object of the present invention relates to a method for restoring the expression of C9orf72 in a patient suffering from Amyotrophic Lateral Sclerosis (ALS) comprising administering to the patient a therapeutically effective amount of a gene editing platform that consists of (a) at least one base-editing enzyme and (b) at least one guide RNA molecule for guiding the base-editing enzyme to at least one target sequence in the RNA Polymerase II pause site located in the first intronic region of the gene C9orf72, thereby editing said site and subsequently increasing the expression of C9orf72.
- a gene editing platform that consists of (a) at least one base-editing enzyme and (b) at least one guide RNA molecule for guiding the base-editing enzyme to at least one target sequence in the RNA Polymerase II pause site located in the first intronic region of the gene C9orf72, thereby editing said site and subsequently increasing the expression of C9orf72.
- the gene editing platform is suitable for introducing some mutations in the RNA Polymerase II pause site. In some embodiments, the gene editing platform is particularly suitable for mutating the base C located at position Chr9:27563356-27563366- Hg18. In some embodiments, the gene editing platform is particularly suitable for introducing one C>T conversion at position Chr9:27563356-27563366-Hg18 ( Figure 1A).
- the base-editing enzyme of the present invention comprises a defective CRISPR/Cas nuclease. The sequence recognition mechanism is the same as for the non- defective CRISPR/Cas nuclease.
- the defective CRISPR/Cas nuclease of the invention comprises at least one RNA binding domain.
- the RNA binding domain interacts with a guide RNA molecule as defined hereinafter.
- the defective CRISPR/Cas nuclease of the invention is a modified version with no nuclease activity. Accordingly, the defective CRISPR/Cas nuclease specifically recognizes the guide RNA molecule and thus guides the base-editing enzyme to its target DNA sequence.
- the defective CRISPR/Cas nuclease can be modified to increase nucleic acid binding affinity and/or specificity, alter an enzymatic activity, and/or change another property of the protein.
- the nuclease domains of the protein can be modified, deleted, or inactivated.
- the protein can be truncated to remove domains that are not essential for the function of the protein.
- the protein is truncated or modified to optimize the activity of the RNA binding domain.
- the CRISPR/Cas nuclease consists of a mutant CRISPR/Cas nuclease i.e. a protein having one or more point mutations, insertions, deletions, truncations, a fusion protein, or a combination thereof.
- the mutant has the RNA-guided DNA binding activity, but lacks one or both of its nuclease active sites.
- the mutant comprises an amino acid sequence having at least 50% of identity with the wild type amino acid sequence of the CRISPR/Cas nuclease.
- CRISPR/Cas nucleases can be used in this invention.
- Non-limiting examples of suitable CRISPR/CRISPR/Cas nucleases include Cas3, Cas4, Cas5, Cas5e (or CasD), Cas6, Cas6e, Cas6f, Cas7, Cas8a1, Cas8a2, Cas8b, Cas8c, Cas9, Cas10, Cas10d, CasF, CasG, CasH, Csy1, Csy2, Csy3, Cse1 (or CasA), Cse2 (or CasB), Cse3 (or CasE), Cse4 (or CasC), Csc1, Csc2, Csa5, Csn2, Csm2, Csm3, Csm4, Csm5, Csm6, Cmr1, Cmr3, Cmr4, Cmr5, Cmr6, Csb1, Csb2, Csb3, Csx17, Csx14, Csx10, Csx16, CsaX, Csx3, Cs
- the CRISPR/Cas nuclease is derived from a type II CRISPR-Cas system. In some embodiments, the CRISPR/Cas nuclease is derived from a Cas9 protein.
- the Cas9 protein can be from Streptococcus pyogenes, Streptococcus thermophilus, Streptococcus sp., Nocardiopsis rougevillei, Streptomyces pristinaespiralis, Streptomyces viridochromogenes, Streptomyces viridochromogenes, Streptosporangium roseum, Streptosporangium roseum, Alicyclobacillus acidocaldarius, Bacillus pseudomycoides, Bacillus selenitireducens, Exiguobacterium sibiricum, Lactobacillus delbrueckii, Lactobacillus salivarius, Microscilla marina, Burkholderiales bacterium, Polaromonas naphthalenivorans, Polaromonas sp., Crocosphaera watsonii, Cyanothece sp., Microcystis aeruginosa, Synechococcus s
- the CRISPR/Cas nuclease is a mutant of a wild type CRISPR/Cas nuclease (such as Cas9) or a fragment thereof. In some embodiments, the CRISPR/Cas nuclease is a mutant Cas9 protein from S. pyogenes.
- Methods for generating a Cas9 protein (or a fragment thereof) having an inactive DNA cleavage domain are known (See, e.g., Jinek et al., Science.337:816-821(2012); Qi et al., “Repurposing CRISPR as an RNA-Guided Platform for Sequence-Specific Control of Gene Expression” (2013) Cell.28; 152(5):1173-83, the entire contents of each of which are incorporated herein by reference).
- the DNA cleavage domain of Cas9 is known to include two subdomains, the HNH nuclease subdomain and the RuvC1 subdomain.
- the HNH subdomain cleaves the strand complementary to the gRNA, whereas the RuvC1 subdomain cleaves the non-complementary strand. Mutations within these subdomains can silence the nuclease activity of Cas9. For example, the mutations D10A and H841A completely inactivate the nuclease activity of S. pyogenes Cas9 (Jinek et al., Science.337:816-821(2012); Qi et al., Cell. 28; 152(5):1173-83 (2013)).
- the CRISPR/Cas nuclease of the present invention is nickase and more particularly a Cas9 nickase i.e.
- the nickase of the present invention comprises the amino acid sequence as set forth in SEQ ID NO:4 or SEQ ID NO:5. SEQ ID NO: 4> S.
- variants of dCas9 are provided which are at least about 70% identical, at least about 80% identical, at least about 90% identical, at least about 95% identical, at least about 98% identical, at least about 99% identical, at least about 99.5% identical, or at least about 99.9% to SEQ ID NO:1.
- variants of dCas9 are provided having amino acid sequences which are shorter, or longer than SEQ ID NO: 1 or 3, by about 5 amino acids, by about 10 amino acids, by about 15 amino acids, by about 20 amino acids, by about 25 amino acids, by about 30 amino acids, by about 40 amino acids, by about 50 amino acids, by about 75 amino acids, by about 100 amino acids or more.
- the second component of the base-editing enzyme herein disclosed comprises a non-nuclease DNA modifying enzyme that is a deaminase. Since, the targeted base of interest is a C, the deaminase is preferably a cytidine deaminase.
- the cytidine deaminase is an apolipoprotein B mRNA-editing complex (APOBEC) family deaminase. In some embodiments, the cytidine deaminase is an APOBEC1 family deaminase. In some embodiments, the cytidine deaminase is an activation-induced cytidine deaminase (AID). In some embodiments, the cytidine deaminase is an ACF1/ASE deaminase.
- APOBEC apolipoprotein B mRNA-editing complex
- the cytidine deaminase is selected from the group consisting of AID: activation induced cytidine deaminase, APOBEC1: apolipoprotein B mRNA editing enzyme, catalytic polypeptide-like 1, APOBEC3A: apolipoprotein B mRNA editing enzyme, catalytic polypeptide-like 3A, APOBEC3B: apolipoprotein B mRNA editing enzyme, catalytic polypeptide-like 3B, APOBEC3C: apolipoprotein B mRNA editing enzyme, catalytic polypeptide-like 3C, APOBEC3D: apolipoprotein B mRNA editing enzyme, catalytic polypeptide-like 3D, APOBEC3F: apolipoprotein B mRNA editing enzyme, catalytic polypeptide-like 3F, APOBEC3G: apolipoprotein B mRNA editing enzyme, catalytic polypeptide-like
- the cytidine deaminase derives from the Activation Induced cytidine Deaminase (AID).
- AID is a cytidine deaminase that can catalyze the reaction of deamination of cytosine in the context of DNA or RNA.
- AID changes a C base to U base. In dividing cells, this could lead to a C to T point mutation.
- the change of C to U could trigger cellular DNA repair pathways, mainly excision repair pathway, which will remove the mismatching U-G base-pair, and replace with a T-A, A-T, C-G, or G-C pair.
- the DNA modifying enzyme is AID* ⁇ that is an AID mutant with increased SHM activity whose Nuclear Export Signal (NES) has been removed (Hess GT, Fresard L, Han K, Lee CH, Li A, Cimprich KA, Montgomery SB, Bassik MC: Directed evolution using dCas9-targeted somatic hypermutation in mammalian cells. Nat Methods 2016, 13(12):1036- 1042).
- the cytidine deaminase consists of a variant of the amino acid sequence as set forth in SEQ ID NO:6-16.
- the deaminase is fused to the C-terminus of the defective CRISPR/Cas nuclease.
- the defective CRISPR/Cas nuclease and the deaminase are fused via a linker.
- the linker comprises a (GGGGS)n (SEQ ID NO:17), a (G)n, an (EAAAK)n (SEQ ID NO: 18), a (GGS)n, or an SGSETPGTSESATPES (SEQ ID NO:19) motif (see, e.g., Guilinger, John P., David B. Thompson, and David R. Liu.
- suitable linker motifs and configurations include those described in Chen et al., Fusion protein linkers: property, design and functionality. Adv Drug Deliv Rev. 2013; 65(10):1357-69, the entire contents of which are incorporated herein by reference.
- the fusion protein may comprise additional features.
- localization sequences such as nuclear localization sequences (NLS), cytoplasmic localization sequences, export sequences, such as nuclear export sequences, or other localization sequences, as well as sequence tags that are useful for solubilization, purification, or detection of the fusion proteins.
- NLS nuclear localization sequences
- cytoplasmic localization sequences such as cytoplasmic localization sequences
- export sequences such as nuclear export sequences, or other localization sequences
- sequence tags that are useful for solubilization, purification, or detection of the fusion proteins.
- Suitable localization signal sequences and sequences of protein tags include, but are not limited to, biotin carboxylase carrier protein (BCCP) tags, myc-tags, calmodulin-tags, FLAG-tags, hemagglutinin (HA)-tags, polyhistidine tags, also referred to as histidine tags or His-tags, maltose binding protein (MBP)-tags, nus-tags, glutathione-S-transferase (GST)-tags, green fluorescent protein (GFP)-tags, thioredoxin-tags, S-tags, Softags (e.g., Softag 1, Softag 3), strep-tags, biotin ligase tags, FlAsH tags, V5 tags, and SBP-tags.
- BCCP biotin carboxylase carrier protein
- MBP maltose binding protein
- GST glutathione-S-transferase
- GFP green fluorescent protein
- Softags e.g., Softag
- CBE base-editing enzymes are known in the art (see e.g. Koblan, Luke W., et al. "Improving cytidine and adenine base editors by expression optimization and ancestral reconstruction.” Nature biotechnology 36.9 (2016): 843-846) and typically include those described in Table A.
- Table A some exemplary base-editing enzymes
- the amino acid sequence of CBE-SpRY is SEQ ID NO:20.
- the guide RNA molecule of the present invention thus comprises a guide sequence for providing the targeting specificity. It includes a region that is complementary and capable of hybridization to a pre-selected target site of interest in the RNA Polymerase II pause site. According to the present disclosure, the guide RNA targets the pause site that is located on chr9:27563356-27563366 region, and more preferably the nucleotide sequence SEQ ID NO:30 (GAAGAGGCGCGGGTAGAAGC). In some embodiment, this guide sequence can comprise from about 10 nucleotides to more than about 25 nucleotides.
- the region of base pairing between the guide sequence and the corresponding target site sequence can be about 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 22, 23, 24, 25, or more than 25 nucleotides in length.
- the guide sequence is about 17-20 nucleotides in length, such as 20 nucleotides.
- a software program is used to identify candidate CRISPR target sequences on both strands of the DNA nucleic acid molecule based on desired guide sequence length and a CRISPR motif sequence (PAM) for a specified CRISPR enzyme.
- PAM CRISPR motif sequence
- Each target sequence and its corresponding PAM site/sequence are referred herein as a Cas-targeted site.
- Type II CRISPR system one of the most well characterized systems, needs only Cas 9 protein and a guide RNA complementary to a target sequence to affect target cleavage.
- target sites for Cas9 from S. pyogenes, with PAM sequences NGG may be identified by searching for 5′-Nx-NGG- 3′ both on the input sequence and on the reverse-complement of the input. Since multiple occurrences in the genome of the DNA target site may lead to nonspecific genome editing, after identifying all potential sites, the program filters out sequences based on the number of times they appear in the relevant reference genome.
- the filtering step may be based on the seed sequence.
- results are filtered based on the number of occurrences of the seed:PAM sequence in the relevant genome.
- the user may be allowed to choose the length of the seed sequence.
- the user may also be allowed to specify the number of occurrences of the seed:PAM sequence in a genome for purposes of passing the filter. The default is to screen for unique sequences. Filtration level is altered by changing both the length of the seed sequence and the number of occurrences of the sequence in the genome.
- the program may in addition or alternatively provide the sequence of a guide sequence complementary to the reported target sequence(s) by providing the reverse complement of the identified target sequence(s). Further details of methods and algorithms to optimize sequence selection can be found in U.S. application Ser. No. 61/836,080; incorporated herein by reference.
- the guide RNA targets a sequence selected from Table 1 (see EXAMPLE).
- the gene editing platform comprises a) a base-editing enzyme that is a CBE-SpRY and b) and at least one guide RNA molecule that targets one sequence selected in Table 1.
- the guide RNA molecule of the present invention can be made by various methods known in the art including cell-based expression, in vitro transcription, and chemical synthesis.
- RNA molecules of the present invention can be made with recombinant technology using a host cell system or an in vitro translation-transcription system known in the art.
- the guide RNA molecule may include one or more modifications. Such modifications may include inclusion of at least one non-naturally occurring nucleotide, or a modified nucleotide, or analogs thereof. Modified nucleotides may be modified at the ribose, phosphate, and/or base moiety. Modified nucleotides may include 2’-O-methyl analogs, 2’- deoxy analogs, or 2’-fluoro analogs.
- the nucleic acid backbone may be modified, for example, a phosphorothioate backbone may be used.
- LNA locked nucleic acids
- BNA bridged nucleic acids
- modified bases include, but are not limited to, 2-aminopurine, 5-bromo-uridine, pseudouridine, inosine, 7-methylguanosine.
- a plurality of guide RNA molecules are designed for targeting a plurality of sequences in the RNA Polymerase II pause site.
- the gene editing platform disclosed herein thus comprises 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, or 20 guide RNA molecules as disclosed herein.
- a plurality of base-editing enzyme along with a plurality of guide RNA molecules are designed for targeting a plurality of sequences in the RNA Polymerase II pause site.
- the gene editing platform disclosed herein thus comprises 2, 3 or 4 base-editing enzymes and 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, or 20 RNA molecules as disclosed herein.
- the different components of the gene editing platform of the present invention are administered to the patient through expression from one or more vectors. Examples of vectors include viral vector and non-viral vectors.
- the term “viral vector” refers to a virion or virus particle that functions as a nucleic acid delivery vehicle and which comprises a vector genome packaged within the virion or virus particle.
- the vector is a viral vector which is an adeno-associated virus (AAV), a retroviral vector, bovine papilloma virus, an adenovirus vector, a vaccinia virus, or a polyoma virus.
- AAV adeno-associated virus
- the viral vector is a AAV vector.
- AAV vector means a vector derived from an adeno- associated virus serotype, including without limitation, AAV1, AAV2, AAV3, AAV4, AAV5, AAV6, AAV7, AAV8, AAV9, and mutated forms thereof.
- AAV vectors can have one or more of the AAV wild-type genes deleted in whole or part, preferably the rep and/or cap genes, but retain functional flanking ITR sequences.
- the viral vector is a retroviral vector.
- retroviral vector refers to a vector containing structural and functional genetic elements that are primarily derived from a retrovirus.
- the retroviral vector of the present invention derives from a retrovirus selected from the group consisting of alpharetroviruses (e.g., avian leukosis virus), betaretroviruses (e.g., mouse mammary tumor virus), gammaretroviruses (e.g., murine leukemia virus), deltaretroviruses (e.g., bovine leukemia virus), epsilonretroviruses (e.g., Walley dermal sarcoma virus), lentiviruses (e.g., HIV-1, HIV-2) and spumaviruses (e.g., human spumavirus).
- alpharetroviruses e.g., avian leukosis virus
- betaretroviruses e.g., mouse mammary tumor virus
- gammaretroviruses e.g., murine leukemia virus
- deltaretroviruses e.g., bovine leukemia virus
- the retroviral vector of the present invention is a replication deficient retroviral virus particle, which can transfer a foreign imported RNA of a gene instead of the retroviral mRNA.
- the retroviral vector of the present invention is a lentiviral vector.
- the term “lentiviral vector” refers to a vector containing structural and functional genetic elements that are primarily derived from a lentivirus.
- the lentiviral vector of the present invention is selected from the group consisting of HIV-1, HIV-2, SIV, FIV, EIAV, BIV, VISNA and CAEV vectors.
- the lentiviral vector is a HIV-1 vector.
- minimum retroviral gene delivery vectors can be prepared from a vector genome, which only contains, apart from the recombinant nucleic acid molecule of the present invention, the sequences of the retroviral genome which are non-coding regions of said genome, necessary to provide recognition signals for DNA or RNA synthesis and processing.
- the retroviral vector genome comprises all the elements necessary for the nucleic import and the correct expression of the polynucleotide of interest (i.e. the base editing platform).
- elements that can be inserted in the retroviral genome of the retroviral vector of the present invention are at least one (preferably two) long terminal repeats (LTR), such as a LTR5' and a LTR3', a psi sequence involved in the retroviral genome encapsidation, and optionally at least one DNA flap comprising a cPPT and a CTS domains.
- LTR long terminal repeats
- the LTR preferably the LTR3', is deleted for the promoter and the enhancer of U3 and is replaced by a minimal promoter allowing transcription during vector production while an internal promoter is added to allow expression of the transgene.
- the vector is a Self-INactivating (SIN) vector that contains a non-functional or modified 3' Long Terminal Repeat (LTR) sequence.
- This sequence is copied to the 5' end of the vector genome during integration, resulting in the inactivation of promoter activity by both LTRs.
- a vector genome may be a replacement vector in which all the viral coding sequences between the 2 long terminal repeats (LTRs) have been replaced by the recombinant nucleic acid molecule of the present invention.
- the retroviral vector genome is devoid of functional gag, pol and/or env retroviral genes. By “functional” it is meant a gene that is correctly transcribed, and/or correctly expressed.
- the retroviral vector genome of the present invention in this embodiment contains at least one of the gag, pol and env genes that is either not transcribed or incompletely transcribed; the expression "incompletely transcribed” refers to the alteration in the transcripts gag, gag-pro or gag-pro-pol, one of these or several of these being not transcribed.
- the retroviral genome is devoid of gag, pol and/or env retroviral genes.
- the retroviral vector genome is also devoid of the coding sequences for Vif-, Vpr-, Vpu- and Nef-accessory genes (for HIV-1 retroviral vectors), or of their complete or functional genes.
- the retroviral vector of the present invention is non replicative i.e., the vector and retroviral vector genome are not able to form new particles budding from the infected host cell. This may be achieved by the absence in the retroviral genome of the gag, pol or env genes, as indicated in the above paragraph; this can also be achieved by deleting other viral coding sequence(s) and/or cis-acting genetic elements needed for particles formation.
- the present invention encompasses use of virus-like particles.
- virus-like particle or “VLP” refers to a structure resembling a virus particle but devoid of the viral genome, incapable of replication and devoid of pathogenicity.
- the particle typically comprises at least one type of structural protein from a virus. Preferably only one type of structural protein is present. Most preferably no other non-structural component of a virus is present.
- virus-like particles can be spontaneously self-assembled by viral structural proteins under appropriate conditions in vitro while excluding the genetic material and potential replication probability.
- virus-like particles with a diameter of approximately 20 to 150 nm, also have the characteristics of nanometer materials, such as large surface area, surface-accessible amino acids with reactive moieties (e.g., lysine and glutamic acid residues), inerratic spatial structure, and good biocompatibility. Therefore, assembled virus-like particles have great potential as a delivery system for specifically carrying a variety of cargos.
- one or more of the zinc finger motifs of the Gag protein is/are substituted by one or more RNA-binding domain(s).
- the RNA-binding domain is the Coat protein of the MS2 bacteriophage, of the PP7 phage or of the Q3 phage, the prophage HK022 Nun protein, the U1A protein or the hPum protein. More preferably, the RNA binding domain is the Coat protein of the MS2 bacteriophage or of the PP7 phage. Even more preferably the RNA-binding domain is the Coat protein of the MS2 bacteriophage. These embodiments are particularly suitable for packaging the mRNA encoding for the apelin polypeptide into the VLP.
- the mRNA encoding for the apelin polypeptide that is encapsuled in the virus particle of the present invention comprises at least one encapsidation sequence.
- encapsidation sequence is meant an RNA motif (sequence and three-dimensional structure) recognized specifically by an RNA-binding domain as above described.
- the encapsidation sequence is a stem-loop motif.
- the encapsidation sequence of the retroviral particle is the stem-loop motif of the RNA of the MS2 bacteriophage or of the PP7 phage such as.
- the stem-loop motif and more particularly the stem-loop motif of the RNA of the MS2 bacteriophage or that of the RNA of the PP7 phage may be used alone or repeated several times, preferably from 2 to 25 times, more preferably from 2 to 18 times, for example from 6 to 18 times.
- the present invention encompasses the use of the LentiFlash® technology that based on non-integrative lentiviral particles constructed using a bacteriophage coat protein and its cognate 19-nt stem loop, to replace the natural lentiviral Psi packaging sequence, in order to achieve active mRNA packaging into the lentiviral particles (Prel A, Caval V, Gayon R, Ravassard P, Duthoit C, Payen E, Maouche-Chretien L, Creneguy A, Nguyen TH, Martin N, Piver E, Sevrain R, Lamouroux L, Leboulch P, Deschaseaux F, Bouée P, Sensébé L, Pagès JC.
- the LentiFlash® technology that based on non-integrative lentiviral particles constructed using a bacteriophage coat protein and its cognate 19-nt stem loop, to replace the natural lentiviral Psi packaging sequence, in order to achieve active mRNA packaging into the lentivi
- the retroviral vectors of the present invention can be produced by any well-known method in the art including by transfection (s) transient (s), in stable cell lines and / or by means of helper virus. Use of stable cell lines may also be preferred for the production of the vectors (Greene, M. R. et al.
- the retroviral vector of the present invention is obtainable by a transcomplementation system (vector/packaging system) by transfecting in vitro a permissive cell (such as 293T cells) with a plasmid containing the retroviral vector genome of the present invention, and at least one other plasmid providing, in trans, the gag, pol and env sequences encoding the polypeptides GAG, POL and the envelope protein(s), or for a portion of these polypeptides sufficient to enable formation of retroviral particles.
- a transcomplementation system vector/packaging system
- permissive cells are transfected with a) transcomplementation plasmid, lacking packaging signal psi and, the plasmid is optionally deleted of accessory genes vif, nef, vpu and / or vpr, b) a second plasmid (envelope expression plasmid or pseudotyping env plasmid) comprising a gene encoding an envelope protein(s) and c) a plasmid vector comprising a recombinant genome retroviral, optionally deleted from the promoter region of the 3 'LTR or U3 enhancer sequence of the 3' LTR, including, between the LTR sequences 5 'and 3' retroviral, a psi encapsidation sequence, a nuclear export element (preferably RRE element of HIV or other retroviruses equivalent), comprising the nucleic acid molecule of the present invention and optionally a promoter and / or a nuclear import sequence (cPPT sequence eg
- the three plasmids used do not contain homologous sequence sufficient for recombination.
- Nucleic acids encoding gag, pol and env cDNA can be advantageously prepared according to conventional techniques, from viral gene sequences available in the prior art and databases.
- the trans-complementation plasmid provides a nucleic acid encoding the proteins retroviral gag and pol. These proteins are derived from a lentivirus, and most preferably, from HIV-1.
- the plasmid is devoid of encapsidation sequence, sequence coding for an envelope, accessory genes, and advantageously also lacks retroviral LTRs.
- the sequences coding for gag and pol proteins are advantageously placed under the control of a heterologous promoter, eg cellular, viral, etc.., which can be constitutive or regulated, weak or strong. It is preferably a plasmid containing a sequence transcomplement ⁇ psi-CMV-gag-pol- PolyA. This plasmid allows the expression of all the proteins necessary for the formation of empty virions, except the envelope glycoproteins.
- the plasmid transcomplementation may advantageously comprise the TAT and REV genes. Plasmid transcomplementation is advantageously devoid of vif, vpr, vpu and / or nef accessory genes.
- gag and pol genes and genes TAT and REV can also be carried by different plasmids, possibly separated. In this case, several plasmids are used transcomplementation, each encoding one or more of said proteins.
- the promoters used in the plasmid transcomplementation, the envelope plasmid and the plasmid vector respectively to promote the expression of gag and pol of the coat protein, the mRNA of the vector genome and the transgene are promoters identical or different, chosen advantageously from ubiquitous promoters or specific, for example, from viral promoters CMV, TK, RSV LTR promoter and the RNA polymerase III promoter such as U6 or H1 or promoters of helper viruses encoding env, gag and pol (i.e.
- the plasmids described above can be introduced into competent cells and viruses produced are harvested.
- the cells used may be any cell competent, particularly eukaryotic cells, in particular mammalian, eg human or animal. They can be somatic or embryonic stem or differentiated. Typically the cells include 293T cells, fibroblast cells, hepatocytes, muscle cells (skeletal, cardiac, smooth, blood vessel, etc.), nerve cells (neurons, glial cells, astrocytes) of epithelial cells, renal, ocular etc.. It may also include, insect, plant cells, yeast, or prokaryotic cells.
- the genes gag, pol and env encoded in plasmids or helper viruses can be introduced into cells by any method known in the art, suitable for cell type considered.
- the cells and the vector system are contacted in a suitable device (plate, dish, tube, pouch, etc...), for a period of time sufficient to allow the transfer of the vector system or the plasmid in the cells.
- the vector system or the plasmid is introduced into the cells by calcium phosphate precipitation, electroporation, transduction or by using one of transfection-facilitating compounds, such as lipids, polymers, liposomes and peptides, etc..
- the calcium phosphate precipitation is preferred.
- the cells are cultured in any suitable medium such as RPMI, DMEM, a specific medium to a culture in the absence of fetal calf serum, etc.
- a suitable medium such as RPMI, DMEM, a specific medium to a culture in the absence of fetal calf serum, etc.
- the retroviral vectors of the present invention may be purified from the supernatant of the cells. Purification of the retroviral vector to enhance the concentration can be accomplished by any suitable method, such as by density gradient purification (e.g., cesium chloride (CsCl)) or by chromatography techniques (e.g., column or batch chromatography).
- CsCl cesium chloride
- chromatography techniques e.g., column or batch chromatography
- the vector of the present invention can be subjected to two or three CsCl density gradient purification steps.
- the vector is desirably purified from cells infected using a method that comprises lysing cells infected with adenovirus, applying the lysate to a chromatography resin, eluting the adenovirus from the chromatography resin, and collecting a fraction containing the retroviral vector of the present invention.
- the vector of the present invention includes "control sequences", which refers collectively to promoter sequences, polyadenylation signals, transcription termination sequences, upstream regulatory domains, origins of replication, internal ribosome entry sites ("IRES"), enhancers, and the like, which collectively provide for the replication, transcription and translation of a coding sequence in a recipient cell.
- nucleic acid sequence is a "promoter" sequence, which is used herein in its ordinary sense to refer to a nucleotide region comprising a DNA regulatory sequence, wherein the regulatory sequence is derived from a gene which is capable of binding RNA polymerase and initiating transcription of a downstream (3'- direction) coding sequence.
- Transcription promoters can include "inducible promoters” (where expression of a polynucleotide sequence operably linked to the promoter is induced by an analyte, cofactor, regulatory protein, etc.), “repressible promoters” (where expression of a polynucleotide sequence operably linked to the promoter is induced by an analyte, cofactor, regulatory protein, etc.), and “constitutive promoters”.
- the different components of the gene editing platform of the present invention are provided to the population of cells through the use of an RNA-encoded system.
- the base-editing system may be provided to the population of cells through the use of a chemically modified mRNA-encoded adenine or cytidine base editor together with modified guide RNA as described in Jiang, T., Henderson, J.M., Coote, K. et al. Chemical modifications of adenine base editor mRNA and guide RNA expand its application scope. Nat Commun 11, 1979 (2020).
- engineered RNA-encoded base-editing enzymes e.g. ABE
- ABE engineered RNA-encoded base-editing enzymes
- modifications consist in uridine depleted mRNAs modified with 5-methoxyuridine: synonymous codons may be introduced to deplete uridines as much as possible without altering the coding sequence and replaced all the remaining uridines with 5-methoxyuridine.
- Said optimized base editing system exhibits higher editing efficiency at some genomic sites compared to DNA-encoded system. It is also possible to encapsulate the modified mRNA and guide RNA into lipid nanoparticle (LNP) for allowing lipid nanoparticle (LNP)-mediated delivery.
- LNP lipid nanoparticle
- the mRNA is formulated using one or more lipid-based structures that include but are not limited to liposomes, lipoplexes, or lipid nanoparticles (Paunovska, Kalina, David Loughrey, and James E. Dahlman. "Drug delivery systems for RNA therapeutics.” Nature Reviews Genetics (2022): 1-16).
- Liposomes are artificially-prepared vesicles which can primarily be composed of a lipid bilayer and can be used as a delivery vehicle for the administration of pharmaceutical formulations.
- Liposomes can be of different sizes such as, but not limited to, a multilamellar vesicle (MLV) which can be hundreds of nanometers in diameter and can contain a series of concentric bilayers separated by narrow aqueous compartments, a small unicellular vesicle (SUV) which can be smaller than 50 nm in diameter, and a large unilamellar vesicle (LUV) which can be between 50 and 500 nm in diameter.
- MLV multilamellar vesicle
- SUV small unicellular vesicle
- LUV large unilamellar vesicle
- Liposome design can include, but is not limited to, opsonins or ligands in order to improve the attachment of liposomes to unhealthy tissue or to activate events such as, but not limited to, endocytosis.
- Liposomes can contain a low or a high pH in order to improve the delivery of the pharmaceutical formulations.
- liposomes such as synthetic membrane vesicles are prepared by the methods, apparatus and devices described in US Patent Publication No. US20130177638, US20130177637, US20130177636, US20130177635, US20130177634, US20130177633, US20130183375, US20130183373 and US20130183372.
- the liposomes are formed from 1,2-dioleyloxy-N,N-dimethylaminopropane (DODMA) liposomes, DiLa2 liposomes from Marina Biotech (Bothell, Wash.), 1,2-dilinoleyloxy-3-dimethylaminopropane (DLin-DMA), 2,2-dilinoleyl-4-(2-dimethylaminoethyl)-[1,3]-dioxolane (DLin-KC2-DMA), and MC3 (as described in US20100324120) and liposomes which can deliver small molecule drugs such as, but not limited to, DOXIL® from Janssen Biotech, Inc. (Horsham, Pa.).
- DOXIL® 1,2-dioleyloxy-N,N-dimethylaminopropane
- the mRNAs can be encapsulated by the liposome and/or it can be contained in an aqueous core which can then be encapsulated by the liposome (see International Pub. Nos. WO2012031046, WO2012031043, WO2012030901 and WO2012006378 and US Patent Publication No. US20130189351, US20130195969 and US20130202684).
- the mRNA is formulated with stabilized plasmid-lipid particles (SPLP) or stabilized nucleic acid lipid particle (SNALP) that have been previously described and shown to be suitable for oligonucleotide delivery in vitro and in vivo (see Wheeler et al. Gene Therapy.
- SPLP stabilized plasmid-lipid particles
- SNALP stabilized nucleic acid lipid particle
- the vector of the present invention is combined with pharmaceutically acceptable excipients, and optionally sustained-release matrices, such as biodegradable polymers, to form pharmaceutical compositions.
- pharmaceutically acceptable excipients such as pharmaceutically acceptable polymers
- pharmaceutically acceptable carrier or excipient refers to a non-toxic solid, semi- solid or liquid filler, diluent, encapsulating material or formulation auxiliary of any type.
- Target the Pol II pause site in the C9orf72 gene using base editing A) Schematic representation of the C9orf72 gene on chromosome 9, depicting C9orf72 exons and the region containing G4C2 hexanucleotides repeats and the location of the Pol II pause site (chr9:27563356-27,563,366 – Hg18). Targets sequences of the sgRNAs are indicated with arrows and aligned with the DNA sequence that they bind to in a stranded-oriented way.
- PRO-seq or PRO-cap genome-wide methods map RNA polymerase active sites and transcription start sites, respectively, and allow to study the relationship between promoter- proximal pausing and the core promoter structure.
- PRO-seq or PRO-cap analyses performed by Watts and colleagues (Watts, Jason A., et al. "Cis elements that mediate RNA polymerase II pausing regulate human gene expression.” The American Journal of Human Genetics 105.4 (2019): 677-688) identified a Pol II pause site in the C9orf72 gene (Cheung et al., personal communication). Our base of interest is located at position Chr9:27563356-27563366-Hg18).
- RNA-mediated and RNA-mediated base editing of the RNA Pol II pause site in K562 cells A) Experimental protocol used for base editing experiments in K562 cells. K562 cells co- transfected with a BE/GFP-expressing plasmid and a sgRNA-expressing plasmid.24 hours post transfection, GFP+ cells were sorted and cultured for 3 to 5 days before DNA extraction and PCR amplification of the target region. Amplicons were subjected to Sanger sequencing. RNA extraction was performed around 7 days post transfection and first-strand cDNAs were obtained by reverse transcription, which was then followed by qPCR. B) Experimental protocol used for base editing experiments in K562 cells.
- a BE/GFP- expressing mRNA and a sgRNA were co-transfected in K562 cells.
- Cells were cultured for 3 to 5 days before DNA extraction and PCR amplification of the target region. Amplicons were subjected to Sanger sequencing. RNA extraction was performed around 7 days post transfection and first-strand cDNAs were obtained by reverse transcription, which was then followed by qPCR.
- Figure 3 A BE/GFP- expressing mRNA and a sgRNA were co-transfected in K562 cells. Cells were cultured for 3 to 5 days before DNA extraction and PCR amplification of the target region. Amplicons were subjected to Sanger sequencing. RNA extraction was performed around 7 days post transfection and first-strand cDNAs were obtained by reverse transcription, which was then followed by qPCR. Figure 3.
- RNA-mediated base editing of the RNA Pol II pause site in K562 cells Frequency of C>T conversion in the C1 base (the C9orf72 Pol II pause site) in K562 and at the C2 (bystander C), as determined by Sanger sequencing followed by EditR analysis.
- Cells were transfected with CBE-SpRY-OPT mRNA, purchased from Trilink in combination with chemically modified C9orf72_1, C9orf72_2, C9orf72_3 and C9orf72_4 sgRNAs.
- EXAMPLE 1 Methods: Cell culture Human erythroleukemia cells (K562) were grown in RPMI 1640 medium supplemented with 10% dialyzed fetal bovine serum, 100 U/mL penicillin, 100 ⁇ g/mL streptomycin and 2 mM glutamine. Cells were maintained in a humidified atmosphere with 5% CO2 at 37oC, with medium renewal every 2–3 days.
- Plasmid used in this study is the CBE-SpRY-OPT (used for in vitro mRNA production) that contains the uridine-depleted coding sequence of pCAG-CBE4max-SpRY-P2A-EGFP (RTW5133) (Addgene #139999), two copies of the 3’ untranslated region (UTR) of the HBB gene, a poly-A sequence of 96 A, and a T7 promoter followed by a G allowing efficient capping (Antoniou et al., under revision).
- sgRNA design We manually designed sgRNAs targeting the identified unique site of RNA Polymerase II pause site in the promoter region of C9orf72 (Table 1).
- oligonucleotides were annealed to create the gRNA protospacer and the duplexes were ligated into the Bbs I-digested MA128 plasmid (provided by M. Amendola, Genethon, France).
- Bbs I-digested MA128 plasmid provided by M. Amendola, Genethon, France.
- RNA-mediated base editing we used chemically modified synthetic sgRNAs harboring 2′-O- methyl analogs and 3′-phosphorothioate nonhydrolyzable linkages at the first three 5′ and 3′ nucleotides (Synthego). Table 1. gRNA target sequences.
- CBE-SpRY-OPT mRNA in vitro transcription CBE-SpRY-OPT mRNA, containing 5-methoxyuridine, capped with Cap1 analog, and subjected to silica membrane purification, was purchased from Trilink.
- Plasmid transfection 2x10 6 K562 cells per condition were transfected with 3 ug of the base editor CBE and 1 ⁇ g of sgRNA of interest (C9orf72_2, C9orf72_3 and C9orf72_4).
- C9orf72_2, C9orf72_3 and C9orf72_4 We used the Cell Line Nucleofector TM Kit V VCA-1003 for K562 cells and the U16 program of Nucleofector 2B. Cells transfected with TE buffer or with the base editor-expressing plasmid only served as negative controls.
- RNA transfection 2x10 5 K562 cells per condition were transfected with 3.0 ⁇ g of the enzyme encoding mRNA, and 3.2 ⁇ g of synthetic sgRNA (C9orf72_1, C9orf72_2, C9orf72_3 and C9orf72_4).
- C9orf72_1, C9orf72_2, C9orf72_3 and C9orf72_4 were transfected with 3.0 ⁇ g of the enzyme encoding mRNA, and 3.2 ⁇ g of synthetic sgRNA (C9orf72_1, C9orf72_2, C9orf72_3 and C9orf72_4).
- P3 Primary Cell 4D-Nucleofector X Kit S Likanza
- CA137 program Nucleofector 4D
- RNA polymerase II RNA polymerase II
- Figure 1A and B RNA polymerase II pausing is a key regulatory step in transcription. RNA Pol II pauses at GC-rich regions, and almost 65% of the pause sites are cytosines (Watts, Jason A., et al. "Cis elements that mediate RNA polymerase II pausing regulate human gene expression.” The American Journal of Human Genetics 105.4 (2019): 677-688).
- CBE-SpRY coupled with C9orf72_3 and C9orf72_4 sgRNAs showed also efficient conversion of the target base C1, but also of C2, located within the base editing window (bystander edit) ( Figure 3A).
- TIDE analysis confirmed the DSB-free nature of base editors, as we detected low frequencies of InDels in base edited samples compared to Cas9 nuclease used in combination with the C9orf72_2, C9orf72_3 or C9orf72_4 sgRNAs (Figure 3B).
- RNA-mediated base editing in K562 cells in the C9orf72 Pol II pause site To establish a clinically relevant method to deliver the base editing system in K562 cells and achieve a higher editing efficiency coupled with minimal toxicity compared to the plasmid transfection, we used a protocol based on transfection of mRNA encoding base editors and chemically modified synthetic sgRNAs (Figure 2B).
- C9orf72_1, C9orf72_2, C9orf72_3 or C9orf72_4lls were kept in culture for 3 to 5 days before DNA extraction and Sanger sequencing of the PCR- amplified target region.
- EditR analysis showed that all the sgRNA were able to modify the target base with efficiencies ranging from 9% (C9orf72_1) to 27% (C9orf72_4) with a variable efficiency of bystander C2 within the editing window, upon RNA-mediated delivery of the base editing system (Figure 5).
- EXAMPLE 2 Experimentation on patient-derived motor neurons Generation of iPSC-derived motor neurons Origin of the cells: A control iPSC line generated by the Stem Cell facility at the host institute (Institut Imagine cell line #Ctr004) was used as a starting material for all the motor neuron derivation studies. iPSC colonies were grown in mTeSR medium in vitronectin (both StemCell) coated dishes and were passaged by enzyme - free dissociation (ReleSR, StemCell) according to the manufacturer’s instructions.
- iMN differentiation To generate motor neurons, we have adapted a published protocol (Maury et al., 2015).
- N2B27 medium consists of a 1:1 ratio of advanced DMEM/F12 (Life Technologies) and Neurobasal medium (Life Technologies), 1% N2 supplement (Life Technologies), 2% B27 supplement minus vitamin A (Life Technologies), 5 mM Glutamax (Life Technologies), 5mM L- Glutamine (Sigma), 1% penicillin/streptomycin (Life Technologies) and 0,1 mM 2 - ME (Life Technologies).
- iPSCs spontaneously aggregated into embryoid bodies (EBs) in suspension in N2B27 medium.
- N2B27 medium 10 ⁇ M ROCK inhibitor Y - 27632, 3 ⁇ M CHIR99021 (TOCRIS), 0, 1 ⁇ M LDN (TOCRIS), 20 ⁇ M SB431542 (TOCRIS) and 10 ⁇ M ascorbic acid (Sigma - Aldrich).
- the medium was changed to N2B27 + 3 ⁇ M CHIR99021, 0,1 ⁇ M LDN, 20 ⁇ M 8SB431542 and 100 nM retinoic acid (Sigma - Aldrich).
- the medium was changed to N2B27 + 0, 1 ⁇ M LDN, 20 ⁇ M SB431542 , 100 nM retinoic acid and 500 nM SAG (TOCRIS).
- the medium was changed to N2B27 + 100 nM retinoic acid and 500 nM SAG.
- the medium was changed to N2B27 + 100 nM retinoic acid, 500 nM SAG and 10 ⁇ M DAPT (TOCRIS).
- the EBs are composed of motor neurons and were dissociated with 0 , 5 % Trypsin (Life Technologies). The obtained motor neurons were then seeded in 96- well plates or 4- well plates (with 10mm coverslips) previously coated with Poly-D-lysine.
- iMN testing For assessing the effect of drugs on neuronal morphology and viability, mature iPSC-derived motor neuron cultures are monitored in real time using the live cell imaging and analysis instrument Incucyte SX5 (Sartorius). A neurite detection mask has been optimized for online measurement of neurite extension and retraction. Viability is monitored live by the uptake of Propidium Iodide which is added to the cell culture medium at a concentration of 1 ⁇ g/ml. Images can be acquired and automatically analyzed every hour for the duration of the drug screening test.
- REFERENCES Throughout this application, various references describe the state of the art to which this invention pertains. The disclosures of these references are hereby incorporated by reference into the present disclosure.
Abstract
L'objectif majeur de la présente invention a été de développer des stratégies thérapeutiques sûres, efficaces et définitives pour la sclérose latérale amyotrophique grâce à l'approche innovante de l'édition de bases. Plus particulièrement, les inventeurs ont identifié un site unique de pause de l'ARN polymérase II dans la région promotrice de C9orf72. Leur approche a donc consisté à muter ce site en utilisant la technologie d'édition de bases pour augmenter la transcription et l'expression de C9orf72. Par conséquent, les approches d'édition de bases qui ciblent le site de pause de l'ARN polymérase II devraient stimuler l'expression de C9orf72 et probablement réduire la toxicité due à l'expression répétée, doublant ainsi le potentiel thérapeutique de la stratégie d'édition du génome. Les inventeurs rapportent ici les résultats obtenus suite à la conception de 4 ARN guides simples (ARNsg) ciblant cette région et présentant une faible activité hors cible prédite. Les premiers résultats obtenus dans des lignées cellulaires montrent un taux efficace d'édition de bases en ciblant le site de pause Pol II de C9orf72 et la régulation à la hausse de C9orf72. En conséquence, la présente invention concerne des approches d'édition de bases pour le traitement de la SLA.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP22306302.5 | 2022-09-02 | ||
EP22306302 | 2022-09-02 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2024047247A1 true WO2024047247A1 (fr) | 2024-03-07 |
Family
ID=83690167
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2023/074086 WO2024047247A1 (fr) | 2022-09-02 | 2023-09-01 | Approches d'édition de bases pour le traitement de la sclérose latérale amyotrophique |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2024047247A1 (fr) |
Citations (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20100324120A1 (en) | 2009-06-10 | 2010-12-23 | Jianxin Chen | Lipid formulation |
WO2012006378A1 (fr) | 2010-07-06 | 2012-01-12 | Novartis Ag | Liposomes à lipides ayant une valeur de pka avantageuse pour la délivrance d'arn |
WO2012030901A1 (fr) | 2010-08-31 | 2012-03-08 | Novartis Ag | Petits liposomes destinés à l'administration d'un arn codant pour un immunogène |
WO2012031043A1 (fr) | 2010-08-31 | 2012-03-08 | Novartis Ag | Liposomes pégylés pour l'apport d'arn codant pour un immunogène |
WO2012031046A2 (fr) | 2010-08-31 | 2012-03-08 | Novartis Ag | Lipides adaptés pour une administration liposomale d'arn codant pour une protéine |
US8202983B2 (en) | 2007-05-10 | 2012-06-19 | Agilent Technologies, Inc. | Thiocarbon-protecting groups for RNA synthesis |
US20130122104A1 (en) | 2009-07-01 | 2013-05-16 | Protiva Biotherapeutics, Inc. | Novel lipid formulations for delivery of therapeutic agents to solid tumors |
US20130177638A1 (en) | 2010-04-09 | 2013-07-11 | Pacira Pharmaceuticals, Inc. | Method for formulating large diameter synthetic membrane vesicles |
WO2013176772A1 (fr) | 2012-05-25 | 2013-11-28 | The Regents Of The University Of California | Procédés et compositions permettant la modification de l'adn cible dirigée par l'arn et la modulation de la transcription dirigée par l'arn |
WO2014144761A2 (fr) | 2013-03-15 | 2014-09-18 | The General Hospital Corporation | Augmentation de la spécificité pour la modification du génome à guidage arn |
US20140273226A1 (en) | 2013-03-15 | 2014-09-18 | System Biosciences, Llc | Crispr/cas systems for genomic modification and gene modulation |
US20140273233A1 (en) | 2013-03-15 | 2014-09-18 | Sigma-Aldrich Co., Llc | Crispr-based genome modification and regulation |
WO2022070107A1 (fr) * | 2020-09-30 | 2022-04-07 | Crispr Therapeutics Ag | Matériaux et méthodes de traitement de la sclérose latérale amyotrophique |
-
2023
- 2023-09-01 WO PCT/EP2023/074086 patent/WO2024047247A1/fr unknown
Patent Citations (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8202983B2 (en) | 2007-05-10 | 2012-06-19 | Agilent Technologies, Inc. | Thiocarbon-protecting groups for RNA synthesis |
US20100324120A1 (en) | 2009-06-10 | 2010-12-23 | Jianxin Chen | Lipid formulation |
US20130122104A1 (en) | 2009-07-01 | 2013-05-16 | Protiva Biotherapeutics, Inc. | Novel lipid formulations for delivery of therapeutic agents to solid tumors |
US20130177633A1 (en) | 2010-04-09 | 2013-07-11 | Pacira Pharmaceuticals, Inc. | Method for formulating large diameter synthetic membrane vesicles |
US20130183372A1 (en) | 2010-04-09 | 2013-07-18 | Pacira Pharmaceuticals, Inc. | Method for formulating large diameter synthetic membrane vesicles |
US20130183373A1 (en) | 2010-04-09 | 2013-07-18 | Pacira Pharmaceuticals, Inc. | Method for formulating large diameter synthetic membrane vesicles |
US20130183375A1 (en) | 2010-04-09 | 2013-07-18 | Pacira Pharmaceuticals, Inc. | Method for formulating large diameter synthetic membrane vesicles |
US20130177638A1 (en) | 2010-04-09 | 2013-07-11 | Pacira Pharmaceuticals, Inc. | Method for formulating large diameter synthetic membrane vesicles |
US20130177637A1 (en) | 2010-04-09 | 2013-07-11 | Pacira Pharmaceuticals, Inc. | Method for formulating large diameter synthetic membrane vesicles |
US20130177634A1 (en) | 2010-04-09 | 2013-07-11 | Pacira Pharmaceuticals, Inc. | Method for formulating large diameter synthetic membrane vesicles |
US20130177636A1 (en) | 2010-04-09 | 2013-07-11 | Pacira Pharmaceuticals, Inc. | Method for formulating large diameter synthetic membrane vesicles |
US20130177635A1 (en) | 2010-04-09 | 2013-07-11 | Pacira Pharmaceuticals, Inc. | Method for formulating large diameter synthetic membrane vesicles |
WO2012006378A1 (fr) | 2010-07-06 | 2012-01-12 | Novartis Ag | Liposomes à lipides ayant une valeur de pka avantageuse pour la délivrance d'arn |
US20130202684A1 (en) | 2010-08-31 | 2013-08-08 | Lichtstrasse | Pegylated liposomes for delivery of immunogen encoding rna |
WO2012031046A2 (fr) | 2010-08-31 | 2012-03-08 | Novartis Ag | Lipides adaptés pour une administration liposomale d'arn codant pour une protéine |
WO2012031043A1 (fr) | 2010-08-31 | 2012-03-08 | Novartis Ag | Liposomes pégylés pour l'apport d'arn codant pour un immunogène |
US20130189351A1 (en) | 2010-08-31 | 2013-07-25 | Novartis Ag | Lipids suitable for liposomal delivery of protein coding rna |
US20130195969A1 (en) | 2010-08-31 | 2013-08-01 | Novartis Ag | Small liposomes for delivery of immunogen encoding rna |
WO2012030901A1 (fr) | 2010-08-31 | 2012-03-08 | Novartis Ag | Petits liposomes destinés à l'administration d'un arn codant pour un immunogène |
WO2013176772A1 (fr) | 2012-05-25 | 2013-11-28 | The Regents Of The University Of California | Procédés et compositions permettant la modification de l'adn cible dirigée par l'arn et la modulation de la transcription dirigée par l'arn |
WO2014144761A2 (fr) | 2013-03-15 | 2014-09-18 | The General Hospital Corporation | Augmentation de la spécificité pour la modification du génome à guidage arn |
US20140273226A1 (en) | 2013-03-15 | 2014-09-18 | System Biosciences, Llc | Crispr/cas systems for genomic modification and gene modulation |
US20140273233A1 (en) | 2013-03-15 | 2014-09-18 | Sigma-Aldrich Co., Llc | Crispr-based genome modification and regulation |
WO2014144592A2 (fr) | 2013-03-15 | 2014-09-18 | The General Hospital Corporation | Utilisation d'arn de guidage tronqués (arng tron) pour une augmentation de la spécificité d'édition génomique guidée par arn |
WO2022070107A1 (fr) * | 2020-09-30 | 2022-04-07 | Crispr Therapeutics Ag | Matériaux et méthodes de traitement de la sclérose latérale amyotrophique |
Non-Patent Citations (61)
Title |
---|
"NCBI", Database accession no. YP_002342100.1 |
ADAMS ET AL., THE BIOCHEMISTRY OF THE NUCLEIC ACIDS, 1992 |
ALTSCHUL ET AL., J. MOL. BIOL., vol. 215, 1990, pages 403 - 410 |
ALTSCHUL ET AL., NAT. GENET., vol. 6, 1994, pages 119 - 129 |
ALTSCHUL ET AL., NUCLEIC ACIDS RES., vol. 25, 1997, pages 3389 - 3402 |
BABIC LEKO MZUPUNSKI VKIRINCICH JSMILOVIC DHORTOBAGYI THOF PRSIMIC G: "C9orf72 Hexanucleotide Repeat Expansion", BEHAVIOURAL NEUROLOGY, 2019, pages 2909168 |
BIGIO EH: "C90RF72, the new gene on the block, causes C9FTD/ALS: new insights provided by neuropathology", ACTA NEUROPATHOLOGICA, vol. 122, no. 6, December 2011 (2011-12-01), pages 653 - 5, XP019984648, DOI: 10.1007/s00401-011-0919-7 |
BRINKMAN, EVA K. ET AL.: "Easy quantitative assessment of genome editing by sequence trace decomposition", NUCLEIC ACIDS RESEARCH, vol. 42, no. 22, 2014, pages e168 - e168, XP055788071, DOI: 10.1093/nar/gku936 |
CAPPELLA, MARISA ET AL.: "Gene therapy for ALS a perspective", INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, vol. 20, no. 18, 2019, pages 4388 |
CHEN ET AL.: "Fusion protein linkers: property, design and functionality.", ADV DRUG DELIV REV., vol. 65, no. 10, 2013, pages 1357 - 69, XP028737352, DOI: 10.1016/j.addr.2012.09.039 |
CHYLINSKI, RHUNCHARPENTIER: "The tracrRNA and Cas9 families of type II CRLSPR-Cas immunity systems", RNA BIOLOGY, vol. 10, no. 5, 2013, pages 726 - 737, XP055116068, DOI: 10.4161/rna.24321 |
CIURA, SORANA ET AL.: "Loss of function of C9orf72 causes motor deficits in a zebrafish model of amyotrophic lateral sclerosis", ANNALS OF NEUROLOGY, vol. 74, no. 2, 2013, pages 180 - 187, XP071640915, DOI: 10.1002/ana.23946 |
CORPET ET AL., NUC. ACIDS RES., vol. 16, 1988, pages 10881 - 10890 |
CRADICK, THOMAS J. ET AL.: "COSMID: a web-based tool for identifying and validating CRISPR/Cas off-target sites", MOLECULAR THERAPY-NUCLEIC ACIDS, vol. 3, 2014, pages e214 |
DEFOUGEROLLES, HUM GENE THER., vol. 19, 2008, pages 125 - 132 |
DELTCHEVA E.CHYLINSKI K.SHARMA C. M.GONZALES K.CHAO Y.PIRZADA Z. A.ECKERTM. P.VOGEL J.CHARPENTIER E.: "CRISPR RNA maturation by trans-encoded small RNA and host factor RNase III.", NATURE, vol. 471, 2011, pages 602 - 607, XP055308803, DOI: 10.1038/nature09886 |
GISHSTATES, NATURE GENET., vol. 3, 1993, pages 266 - 272 |
GREENE, M. R. ET AL.: "Transduction of Human CD34 + Repopulating Cells with a Self-Inactivating Lentiviral Vector for SCID-X1 Produced at Clinical Scale by a Stable Cell Line.", HUM. GENE THER. METHODS, vol. 23, 2012, pages 297 - 308, XP055503306, DOI: 10.1089/hgtb.2012.150 |
GUILINGER, JOHN P.DAVID B. THOMPSONDAVID R. LIU: "Fusion of catalytically inactive Cas9 to FokI nuclease improves the specificity of genome modification", NATURE BIOTECHNOLOGY, vol. 32, no. 6, 2014, pages 577 - 582, XP055157221, DOI: 10.1038/nbt.2909 |
HESS GTFRESARD LHAN KLEE CHLI ACINPRICH KAMONTGOMERY SBBASSIK MC: "Directed evolution using dCas9-targeted somatic hypermutation in mammalian cells", NAT METHODS, vol. 13, no. 12, 2016, pages 1036 - 1042, XP055832741, DOI: 10.1038/nmeth.4038 |
HEYES ET AL., J CONTR REL., vol. 107, 2005, pages 276 - 287 |
HIGGINSSHARP, CABIOS, vol. 4, 1989, pages 151 - 153 |
HIGGINSSHARP, GENE, vol. 73, 1988, pages 237 - 244 |
HUANG ET AL., COMP. APPLS BIOSCI., vol. 8, 1992, pages 155 - 16 |
J. J., MCSHAN W. M.AJDIC D. J.SAVIC D. J.SAVIC G.LYON K.PRIMEAUX C.SEZATE S.SUVOROV A. N.KENTON S.LAI H. S.: "Complete genome sequence of an M1 strain of Streptococcus pyogenes", PROC. NATL. ACAD. SCI. U.S.A., vol. 98, 2001, pages 4658 - 4663 |
JEFFS ET AL., PHARM RES., vol. 22, 2005, pages 362 - 372 |
JIANG, T.HENDERSON, J.M.COOTE, K. ET AL.: "Chemical modifications of adenine base editor mRNA and guide RNA expand its application scope", NAT COMMUN, vol. 11, 2020, pages 1979, XP055905003, DOI: 10.1038/s41467-020-15892-8 |
JINEK ET AL., SCIENCE, vol. 337, 2012, pages 16 - 821 |
JINEK M.CHYLINSKI K.FONFARA 1.HAUER M.DOUDNA J. A.CHARPENTIER E.: "A programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity", SCIENCE, vol. 337, 2012, pages 816 - 821, XP055229606, DOI: 10.1126/science.1225829 |
JUDGE ET AL., J CLIN INVEST., vol. 119, 2009, pages 661 - 673 |
KLUESNER, MITCHELL G. ET AL.: "EditR: a method to quantify base editing from Sanger sequencing", THE CRISPR JOURNAL 1, vol. 3, 2018, pages 239 - 250, XP055715954, DOI: 10.1089/crispr.2018.0014 |
KLUESNER, MITCHELL G. ET AL.: "EditR: a method to quantify base editing from Sanger sequencing", THE CRISPR JOURNAL, vol. 1, no. 3, 2018, pages 239 - 250, XP055715954, DOI: 10.1089/crispr.2018.0014 |
KOBLAN, LUKE W.: "Improving cytidine and adenine base editors by expression optimization and ancestral reconstruction", NATURE BIOTECHNOLOGY, vol. 36, no. 9, 2018, pages 843 - 846, XP036929657, DOI: 10.1038/nbt.4172 |
KOSICKI, MICHAEL, KART TOMBERG, ALLAN BRADLEY: "Repair of double-strand breaks induced by CRISPR-Cas9 leads to large deletions and complex rearrangements", NATURE BIOTECHNOLOGY, vol. 36, no. 8, 2018, pages 765 - 771, XP036929645, DOI: 10.1038/nbt.4192 |
MADDEN ET AL., METH. ENZYMOL., vol. 266, 1996, pages 131 - 141 |
MICCIO ANNARITA ET AL: "Novel genome-editing-based approaches to treat motor neuron diseases: Promises and challenges", MOLECULAR THERAPY, vol. 30, no. 1, 1 January 2022 (2022-01-01), US, pages 47 - 53, XP093015223, ISSN: 1525-0016, DOI: 10.1016/j.ymthe.2021.04.003 * |
MINGAJ X ET AL: "P.0208 Base editing therapeutic strategies for motor neuron diseases", EUROPEAN NEUROPSYCHOPHARMACOLOGY, ELSEVIER SIENCE PUBLISHERS BV , AMSTERDAM, NL, vol. 53, 1 December 2021 (2021-12-01), XP086908044, ISSN: 0924-977X, [retrieved on 20211230], DOI: 10.1016/J.EURONEURO.2021.10.201 * |
MORRISSEY ET AL., NAT BIOTECHNOL., vol. 2, 2005, pages 1002 - 1007 |
NEEDLEMAN, SAUL B.WUNSCH, CHRISTIAN D.: "A general method applicable to the search for similarities in the amino acid sequence of two proteins", JOURNAL OF MOLECULAR BIOLOGY, vol. 48, no. 3, 1970, pages 443 - 53, XP024011703, DOI: 10.1016/0022-2836(70)90057-4 |
NEEDLEMANWUNSCH, J. MOL. BIOL., vol. 48, 1970, pages 443 |
PAUNOVSKA, KALINADAVID LOUGHREYJAMES E. DAHLMAN: "Drug delivery systems for RNA therapeutics", NATURE REVIEWS GENETICS, 2022, pages 1 - 16 |
PEARSON ET AL., METH. MOL. BIOL., vol. 24, 1994, pages 307 - 31 |
PEARSONLIPMAN, PROC. NATL. ACAD. SCI. U.S.A., vol. 85, 1988, pages 2444 |
PREL ACAVAL IGAYON RRAVASSARD PDUTHOIT CPAYEN EMCIOUCHE-CHRETIEN LCRENEGUY ANGUYEN THMARTIN A: "Highly efficient in vitro and in vivo delivery o RNAs using new versatile MS2-chimeric retrovirus-like particles", MOL THER METHODS CLIN DEV., vol. 2, 21 October 2015 (2015-10-21), pages 15039, XP002768084, DOI: 10.1038/mtm.2015.39 |
QI ET AL., CELL, vol. 152, no. 5, 2013, pages 1173 - 83 |
QI ET AL.: "Repurposing CRISPR as an RNA-Guided Platform for Sequence-Specific Control of Gene Expression", CELL, vol. 152, no. 5, 2013, pages 1173 - 83, XP055346792, DOI: 10.1016/j.cell.2013.02.022 |
REES, HOLLY A.DAVID R. LIU: "Base editing: precision chemistry on the genome and transcriptome of living cells", NATURE REVIEWS GENETICS, vol. 19, no. 12, 2018, pages 770 - 788, XP036637441, DOI: 10.1038/s41576-018-0068-0 |
SELLIER, CHANTAL: "Loss of C9 ORF 72 impairs autophagy and synergizes with polyQ Ataxin - 2 to induce motor neuron dysfunction and cell death", THE EMBO JOURNAL, vol. 35, no. 12, 2016, pages 1276 - 1297 |
SEMPLE ET AL., NATURE BIOTECH., vol. 28, 2010, pages 172 - 176 |
SHI, YINGXIAO ET AL.: "Haploinsufficiency leads to neurodegeneration in C90RF72 ALS/FTD human induced motor neurons", NATURE MEDICINE, vol. 24, no. 3, 2018, pages 313 - 325, XP055973357, DOI: 10.1038/nm.4490 |
SMITHWATERMAN, ADV. APPL. MATH., vol. 2, 1981, pages 482 |
TIJSSEN: "Laboratory Techniques In Biochemistry And Molecular Biology-Hybridization With Nucleic Acid Probes Part I", 1993, ELSEVIER, article "Overview of principles of hybridization and the strategy of nucleic acid probe assay" |
WALTON, RUSSELL Σ ET AL.: "Unconstrained genome targeting with near-PAM less engineered CRISPR-Cas9 variants", SCIENCE, vol. 368, no. 6488, 2020, pages 290 - 296 |
WATTS, JASON A. ET AL.: "Cis elements that mediate RNA polymerase II pausing regulate human gene expression", THE AMERICAN JOURNAL OF HUMAN GENETICS, vol. 105, no. 4, 2019, pages 677 - 688, XP085849312, DOI: 10.1016/j.ajhg.2019.08.003 |
WHEELER ET AL., GENE THERAPY., vol. 6, 1999, pages 1438 - 1447 |
YINGXIAO SHI ET AL: "Haploinsufficiency leads to neurodegeneration in C9ORF72 ALS/FTD human induced motor neurons", NATURE MEDICINE, vol. 24, no. 3, 5 February 2018 (2018-02-05), New York, pages 313 - 325, XP055497485, ISSN: 1078-8956, DOI: 10.1038/nm.4490 * |
YUN YEOMIN ET AL: "CRISPR/Cas9-Mediated Gene Correction to Understand ALS", INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, vol. 21, no. 11, 27 May 2020 (2020-05-27), pages 3801, XP093015226, DOI: 10.3390/ijms21113801 * |
ZHANG, XIAOHUI ET AL.: "Dual base editor catalyzes both cytosine and adenine base conversions in human cells", NATURE BIOTECHNOLOGY, vol. 38, no. 7, 2020, pages 856 - 860, XP037187540, DOI: 10.1038/s41587-020-0527-y |
ZHANGMADDEN, GENOME RES., vol. 7, 1997, pages 49 - 656 |
ZHU, QIANG ET AL.: "Reduced C9ORF72function exacerbates gain of toxicity from ALS/FTD-causing repeat expansion in C9orf72", NATURE NEUROSCIENCE, vol. 23, no. 5, 2020, pages 615 - 624, XP037099667, DOI: 10.1038/s41593-020-0619-5 |
ZIMMERMANN ET AL., NATURE, vol. 441, 2006, pages 111 - 114 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US11624078B2 (en) | Protected guide RNAS (pgRNAS) | |
US20240093193A1 (en) | Dead guides for crispr transcription factors | |
US20240117382A1 (en) | DELIVERY, USE AND THERAPEUTIC APPLICATIONS OF CRISPR SYSTEMS AND COMPOSITIONS FOR GENOME EDITING AS TO HEMATOPOIETIC STEM CELLS (HSCs) | |
CN106795488B (zh) | 用于造血干细胞中核酸酶介导的基因组工程化和校正的方法和组合物 | |
EP3237615B2 (fr) | Crispr présentant ou associé avec un domaine de déstabilisation | |
EP3494997B1 (fr) | Protéines de liaison à l'adn inductibles, outils de perturbation du génome et leurs applications | |
JP2020508685A (ja) | サプレッサーtRNA及びデアミナーゼによる変異のRNAターゲティング | |
JP2016521555A5 (fr) | ||
CA3152288A1 (fr) | Compositions et procedes pour le traitement de troubles associes a l'adn repetitif | |
US11492614B2 (en) | Stem loop RNA mediated transport of mitochondria genome editing molecules (endonucleases) into the mitochondria | |
US20240052371A1 (en) | Programmable transposases and uses thereof | |
WO2022119881A1 (fr) | Inactivation différentielle d'un allèle hétérozygote de lrrk2 | |
WO2021216674A1 (fr) | Plateformes d'édition génétique thérapeutique à médiation par cas 12a/nls améliorées | |
WO2024047247A1 (fr) | Approches d'édition de bases pour le traitement de la sclérose latérale amyotrophique | |
EP4150081A1 (fr) | Approches d'édition de bases pour le traitement de bétahémoglobinopathies | |
US20230348878A1 (en) | ENHANCEMENT OF SAFETY AND PRECISION FOR CRISPR-Cas INDUCED GENE EDITING BY VARIANTS OF DNA POLYMERASE USING CAS-PLUS VARIANTS | |
US20220064635A1 (en) | Crispr compositions and methods for promoting gene editing of adenosine deaminase 2 (ada2) | |
Rathbone | Nonviral Approaches for Delivery of CRISPR-Cas9 Into Hepatocytes for Treatment of Inherited Metabolic Disease | |
Nguyen | CRISPR/Cas9-mediated Homology Directed Repair disease modeling and lentiviral gene therapy for CDKL5 deficiency disorder | |
JP2023553701A (ja) | 先天性筋ジストロフィーの処置のための治療用lama2ペイロード | |
CA3226445A1 (fr) | Inactivations du virus de l'hepatite b (vhb) | |
WO2023052366A1 (fr) | Approches d'édition de bases pour le traitement de bétahémoglobinopathies | |
JP2023546694A (ja) | 新規のomni56、58、65、68、71、75、78及び84crisprヌクレアーゼ | |
AU2022232622A1 (en) | Strategies for knock-ins at c3 safe harbor sites |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 23764895 Country of ref document: EP Kind code of ref document: A1 |